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ABSTRACT
Clostridium difficile infection (CDI), caused by the anaerobic spore-former C. difficile, is
a major cause of health-care associated morbidity. CDI occurs in individuals that have a
disrupted GI tract microbiota, typically in patients who are on antibiotic therapy. After recovery
from an episode of CDI, approximately, 15-30% of patients experience relapse of disease. The
mechanism of relapse is not well understood. It is plausible for relapse to occur if C. difficile
cells and spores associate with the GI tract mucosa during infection and persist after infection.
However, little is known about the association of cells and spores with the GI tract mucosa
during and after infection. To address this gap in knowledge, I visualized C. difficile vegetative
cells by performing fluorescence in situ hybridization, using a 16S rRNA probe, and C. difficile
spores by performing immunofluorescence microscopy, using anti-HMW SlpA antibodies, in the
mouse cecum and colon both during (2-10 days post-infection) and after infection (15-40 days
post-infection). C. difficile cells and spores were present in the outer mucus layer and rarely
associated with the inner mucus layer or the epithelium during and after infection in the cecum
and colon. I also determined whether the C. difficile cell surface layer protein A (SlpA), which is
associated with the C. difficile spore surface, mediates spore adhesion to mucin in vitro. Even
though the results of our assay did not indicate an interaction between SlpA on the surface of
spores and mucin, other approaches could be successful in measuring this interaction.
Collectively, the results from this study suggest that association of C. difficile vegetative cells
and spores with the outer mucus layer during infection might be an important step in
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colonization. We suggest that after infection, the association of vegetative cells and spores with
the outer mucus layer might be important in relapse of disease.
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CHAPTER ONE
REVIEW OF LITERATURE
Introduction
Clostridium difficile is a Gram positive, spore forming, obligate anaerobe that causes C.
difficile infection (CDI). There are approximately 450,000 cases and 29,000 deaths that occur
due to CDI each year in the United States (1, 2). CDI is characterized by severe diarrhea and, in
some cases, pseudomembranous colitis, which is inflammation of the colon (3). The infection
typically occurs in patients who ingest C. difficile spores while undergoing antibiotic therapy.
The disruption of the intestinal microbiota due to antibiotic therapy is a prerequisite for infection.
Once spores germinate to form vegetative cells within the small intestines, the vegetative cells
colonize the large intestines and produce toxins that cause symptoms of disease. In a hospital
setting, CDI is especially prevalent, since patients are on antibiotic therapy and are in an
environment where the infections particle, the C. difficile spore, is abundant. After an initial
episode of CDI resolves, recurrence of infection is relatively common, as approximately onefifth of patients that have had CDI will experience recurrence of disease (4).
The mechanism of recurrence is not yet known. However, the persistence of C. difficile
spores and cells from the initial infection within the gastrointestinal (GI) tract is a very plausible
mechanism for recurrent disease. As part of the treatment for CDI, broad-spectrum antibiotics
are generally administered (4). These antibiotics lead to the disruption of the GI tract microbiota
and make a patient that is recovering from CDI susceptible to recurrence (5). In these patients, if
there is persistence of C. difficile spores and vegetative cells from the initial infection, then there
1
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is potential for recurrence. For spores and vegetative cells to persist within the GI tract, they
would have to adhere to the luminally exposed mucus layer. Interestingly, there is evidence that
during infection, C. difficile vegetative cells reside within the outer mucus layer (6). Whether
spores and cells persist within the mucus layer after infection is not known, resulting in a major
gap in knowledge.
By binding to the GI tract mucus layer, spores and cells could persist within the GI tract
after infection has resolved and cause recurrent disease. This adhesion to the mucus layer is most
likely mediated by proteins located on the surface of cells and spores. The vegetative cell surface
layer protein A (SlpA) has been implicated in mediating adhesion between C. difficile cells and
intestinal epithelial cells (7). Therefore, it is plausible that SlpA mediates adhesion between C.
difficile and the GI tract mucus layer as well. Interestingly, our lab has found that SlpA is located
on the surface of C. difficile spores. The role of SlpA in mediating adhesion of C. difficile spores
to mucus is not yet known. However, if spores bind to the mucus layer via SlpA, they have the
potential to persist within the mucus layer and germinate into vegetative cells that cause another
cycle of disease. The adhesion of spores to the host mucosa can create a dormant reservoir that is
maintained after infection has resolved, which has the potential to germinate to form vegetative
cells and cause relapsing disease. C. difficile spores have unique resistance properties, unlike
vegetative cells, that would allow them to survive and persist within the host for extended
periods of time (6, 8).
Taken together, our observations suggest a model of relapsing disease in which spores
colonize and bind to the mucus layer via SlpA, causing persistence after infection that can
initiate another cycle of disease. Therefore, this study aims to test whether C. difficile spores
persist within the mucus layer during infection and whether both cells and spores persist within
the mucus layer after infection by employing a CDI mouse model of infection and localizing C.
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difficile cells and spores within the mouse large intestines via fluorescence microscopy. We will
also quantify spores located within the lumen and associated with the mucosa both during and
after active infection. To determine whether spores bind the mucus layer via SlpA in vivo, we
will design an in vitro mucin adhesion assay that will determine whether adhesion between
spores and mucin is SlpA dependent. The assay will measure adhesion between spores that have
SlpA blocked, using SlpA antibodies, and mucin coated microtiter wells.
C. difficile Infection and Recurrence
CDI initiates when an individual with a disrupted microbiota ingests C. difficile spores.
Ingested C. difficile spores that encounter germinants, including cholate-derived bile acids,
within the small intestines outgrow to form cells (9). These cells colonize the large intestines,
specifically the cecum and colon. Once cells have colonized, strains that are toxigenic begin to
secret toxins. These toxigenic strains produce two main types of toxins, Toxin A and/or Toxin B,
that act on intestinal epithelial cells (10). Both toxins are glucosyltransferases that disrupt
intercellular signaling and ultimately cause cellular apoptosis (11). This disruption of the gut
mucosal barrier leads to recruitment of immune cells, inflammation, and symptoms of disease
(10). It is important to note that toxin production is necessary for disease. Once patients have
recovered from this initial episode of CDI, approximately, 15-30% of these patients will have
recurrence of disease (4). However, the cause of this high rate of recurrence is not well
understood.
There are two main spore reservoirs that can be the source of CDI recurrence. One of
these reservoirs is the external environment of the host and another is within the GI tract of the
host. Recurrence of CDI in most patients occurs within 15 days after cessation of antibiotic
therapy that is used to treat the initial infection (4, 12). Paradoxically, the antibiotics that are
used to treat the initial infection, such as vancomycin and metronidazole, are one of the major
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risk factors for recurrence (Figure 1) (4, 5). With the GI tract susceptible to another episode of
CDI, due to the disruption of the microbiota caused by these antibiotics, spores that are ingested
from the external environment can cause reinfection (Figure 1). Also, spores or cells that have
persisted in the GI tract from the initial infection have the potential to cause relapsing disease
(Figure 1). Ultimately, both reinfection and relapse cause recurrence of CDI. However, studies of
recurrence show that relapse with the same isolate that caused the initial infection occurs more
than 50% of the time, as compared to reinfection with a different isolate, indicating that relapse,
rather than reinfection, is the more likely cause of recurrence (4, 12). We should note that
reinfection with the same isolate is also a possibility in these studies, but this possibility was not
investigated.

Figure 1. Schematic of CDI Recurrence Caused by Relapse or Reinfection. As treatment for
the initial episode of CDI, antibiotics (ABX) are administered. These antibiotics are a major risk
factor for recurrence. Even though most patients recover from CDI after antibiotic treatment, a
minority of patients experience recurrence, which can occur through relapse and/or reinfection
(2, 46, 61). Reinfection can occur from spores that enter the GI tract from the environment, and
relapse can occur from spores or cells that persist within the GI tract from the initial infection.
Red arrows indicate path to recurrence. Orange, ellipsoid-shaped objects depict C. difficile
spores. Green, rod-shaped objects depict C. difficile cells.
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Mucosa of the Large Intestines
As C. difficile colonizes the large intestines, cells and spores come in direct contact with a
complex multilayered structure called the mucosa. The mucosa is composed of three major cellular
layers, which from the apical to the basal orientation include the intestinal epithelium, lamina
propria, and the muscularis mucosae (Figure 2A) (13). The intestinal epithelium is composed of
two main types of cells including ciliated columnar epithelial cells and goblet cells (13). Goblet
cells secret mucin, which extrudes out of the opening of the crypts, and coats the surface of the
tissue. Underlying the intestinal epithelium is the lamina propria which serves supportive and
protective roles. It is composed of loose connective tissue, which provides structural support, and
gut-associated lymphoid tissue, which provides immune defense to the mucosal tissue (13).
Separating the mucosa from the underlying submucosa is a thin layer of smooth muscle called the
muscularis mucosae (13).
Interestingly, enteric bacteria have developed mechanisms to adhere to the luminally
exposed constituents of the mucosa to initiate colonization (14, 15, 16). These luminally exposed
constituents of the mucosa include the mucus layer, intestinal epithelium, and the extracellular
matrix (ECM) (Figure 2B). The mucus layer, which is divided into the outer and inner layer, lines
the lumen and is composed of glycoproteins called mucins (14). The outer mucus layer has a lower
density of mucin, than the inner mucus layer, and is colonized by the microbiota (14). The inner
mucus layer, which resides on the apical surface of intestinal epithelial cells is normally void of
bacteria (14). Enteric bacteria, including pathogenic and commensals, have evolved mechanisms
that allow adhesion to mucin. Commensals, such as lactic acid bacteria, have proteins on their
surface which contain mucin-binding domains that allow attachment to mucin (17, 18). Pathogenic
bacteria also bind to mucin via surface proteins, and structures including fimbriae and flagella
(17). Surrounding the intestinal epithelial cells is the ECM. The ECM includes glycoproteins, such
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as fibronectin and vitronectin. These glycoproteins bind to receptors on the surface of intestinal
epithelial cells and serve as molecular connectors between the cells and structural components
within the ECM, keeping the intestinal epithelium in place (19). Many bacteria, both Grampositive and Gram-negative, have surface proteins that can bind epithelial cells, utilizing these
ECM glycoproteins as molecular bridges (15, 16). By binding to parts of the mucosa that are
exposed to the lumen, both commensals and pathogenic bacteria can initiate colonization within
the host GI tract.

Figure 2. Schematic Depicting Mucosa of the Large Intestines. A) The three major cellular
layers of the cecal and colonic mucosa include the intestinal epithelium, lamina propria, and the
muscularis mucosae. The structure of the intestinal epithelium and lamina propria form strawlike structures called crypts. These crypts are lined by goblet cells that secrete mucus. The
secreted mucus exits through the opening of the crypts and coats the surface of the tissue (not
depicted). Schematic hand drawn by Margret Bradley (M.S.). B) Enteric bacteria are known to
bind luminally exposed constituents of the mucosa including the mucus layer, intestinal
epithelium, and the extracellular matrix. The mucus layer is composed of the outer mucus layer,
where the microbiota resides, and the inner mucus layer. The intestinal epithelium is composed
of two main cell types, including goblet cells and columnar epithelial cells. Surrounding these
cells is the extracellular matrix.
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C. difficile As A Member of the Gut Microbiota
Even though C. difficile is detectable in a small sub-population of healthy individuals, it is
not considered a member of the normal adult GI tract microbiota. In a recent study that looked at
C. difficile abundance relative to the overall gut microbiota, 18 out of 211 healthy individuals had
detectable amounts of C. difficile, using high-resolution 16S rRNA gene sequencing (20). In these
individuals, C. difficile abundance was 0.008% on average relative to the overall gut microbiome
(20). In comparison, individuals who were diagnosed with CDI had an average C. difficile
abundance of 1.78% relative to their gut microbiome (20). Interestingly, although C. difficile is
not normally a member of the adult gut microbiota, up to 50% of infants are asymptomatically
colonized with C. difficile (21). Colonization is at its peak early in infancy (first month) and
continues to drop for the first year and eventually ceases within two years of age (21). The reason
for this decrease and loss in colonization is not known but is correlated with changes in diversity
of the microbiota in developing infants (22).
C. difficile Cell Colonization and Persistence
As one of the initial steps during colonization of the large intestines, C. difficile cells
likely adhere to the GI tract mucosa. However, little is known about this process. In vitro assays
have demonstrated that C. difficile cells adhere to mucus, intestinal epithelial cell lines, and ECM
glycoproteins (7, 16, 23, 24). Multiple proteins that have adhesive properties are characterized in
C. difficile, such as flagellar proteins (FliC, FliD) and cell wall proteins (Cwp66, Cwp84), but
minimal work has been done to identify the cognate host receptors (25).
Even though the initial steps in colonization are not yet clear, we know that during
infection, C. difficile cells colonize the outer mucus layer through in vivo studies. A recent study
conducted by our lab demonstrated that infection with an epidemic strain, BI-17, leads to
colonization within the outer mucus layer in a mouse model of CDI (6). By performing
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fluorescence microscopy, C. difficile cells were found to be a minority amongst the mucosallyassociated bacterial communities within the outer mucus layer in both the cecum and colon
throughout infection (1 to 8 days post-infection (PI)). While the majority of C. difficile cells were
present within the lumen, rarely were cells observed within the inner mucus layer or associated
with the epithelium. These results are corroborated by other studies that demonstrate association
of C. difficile cells with the mucus layer that overlay tissue surfaces within the GI tract in both
the mouse and hamster models of infection (6, 26, 27). These findings suggest that association of
C. difficile cells with the outer mucus layer during infection is an important initial step in GI tract
colonization. Whether cells continue to persist within the outer mucus layer after infection is not
known but can have important implications for relapsing disease.
Persistence of cells within the outer mucosa after infection could either cause relapse or
an asymptomatic carrier state. An asymptomatic carrier state of a patient occurs when detectable
levels of C. difficile are present, but without clinical symptoms (28). Most studies that examine
relapse or an asymptomatic carrier state in either animal models or humans do not focus on
persistence of cells directly, but rather spores (29, 30). The technique commonly used in these
studies involves quantification of spores, specifically, which is done by obtaining colony forming
unites (CFUs) from feces that are exposed to the aerobic environment. Even though C. difficile
cells are culturable from feces exposed to atmospheric oxygen, the feces must be plated within
two hours to prevent loss of cell viability (29). Ultimately, there is minimal, if any data, that
examines persistence of cells within the GI tract after infection. We have a gap in knowledge as
to the persistence and location of C. difficile cells within the GI tract after infection that can
impact our understanding of relapsing disease.

9
C. difficile Spore Resistance Properties
The dormant C. difficile spore is poised to protect the bacterial genome from
environmental stressors and transmit the bacteria from host-to-host. The inner most compartment
of the spore called the core houses the bacterial chromosome, and the outermost layer that
encircles the spore is the coat (31). The coat is a proteinaceous layer that protects the bacterial
genome within the core, providing the spore with most of its resistance properties (31). There are
a multitude of environmental stressors that have been applied to C. difficile spores as part of a
decontamination strategy that demonstrate their resistance properties, which are unique to spores,
and not present in vegetative cells. C. difficile spores are resistant to oxidative stress and
chemical agents, such as hydrogen peroxide and ethanol, which are commonly used in a hospital
setting for decontamination (32). Spores can survive for long periods of time outside the host in
environments that would be inhospitable to vegetative cells, particularly due to atmospheric
oxygen, thereby providing the opportunity for transmission to a new host.
The C. difficile spore has specific resistance properties that aid in persistence within the
host GI tract. For example, C. difficile spores are insensitive to specific aspects of the host innate
immune system. Phagocytosis of C. difficile spores by macrophages does not alter spore viability
and spore ultrastructure, indicating that spores are resistant to the antimicrobial activity of the
phagosome (8). Furthermore, infection of macrophage cell monolayer with C. difficile spores
results in macrophage cell membrane disruption and loss of macrophage cell viability (8). These
data indicate that not only are C. difficile spores insensitive to phagocytosis by macrophages, but
can cause macrophage cell death, the mechanism of which is not known (8). C. difficile spores,
unlike cells, are also insensitive to antibiotics that are administered as part of the treatment for
CDI (6). Both metronidazole and vancomycin are antibiotics commonly prescribed by clinicians
to treat CDI. However, neither medications target C. difficile spores. Metronidazole’s mechanism
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of action entails inhibition of bacterial DNA synthesis and vancomycin inhibits bacterial cell
wall synthesis (33). Since spores are not metabolically active and do not replicate, these drugs
are unable to target spores. Therefore, C. difficile spores are more likely to persist within the GI
tract even after antibiotic treatment.
C. difficile Spore Persistence
C. difficile spores likely bind to the mucosa during infection and persist within the GI
tract after infection. However, the specific mucosal surface that spores bind to during infection in
vivo is not known. In vitro assays have demonstrated that C. difficile spores can bind to mucus,
intestinal epithelial cells, and ECM glycoproteins, including fibronectin and vitronectin (23, 34,
53). These data argue that spore binding to the GI tract mucosa during infection can cause
persistence within the GI tract after infection.
The presence of C. difficile spores within the GI tract after infection would be necessary
if spores cause relapsing disease. Interestingly, persistence of C. difficile spores after infection
has been documented. Multiple studies in humans as well as in animal models have shown that
fecal spore shedding continues to occur long after exposure (29, 30, 35). In an atypical murine
model of CDI, where mice were not pretreated with antibiotics, challenge with C. difficile
resulted in consistently low levels of fecal spore shedding, which occurred for multiple months
post-challenge (29). These mice were considered as asymptomatic carriers of C. difficile, a state
that has been observed in humans as well (29, 30). Approximately, two-thirds of patients that
have had CDI become asymptomatic carriers of C. difficile (30). Not only can asymptomatic
patients contribute to transmission of disease but are also susceptible to relapse (30). Therefore,
since spores persist within the GI tract after infection, they can cause relapsing disease.
If spores persist within the GI tract after infection, then sporulation must be important for
persistence, which is the case. In spore forming species, one of the key transcriptional regulators
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that commit a cell to sporulation is Spo0A (9). Mutations in the spo0A gene result in complete
abolition of spore formation (9). In a murine model of CDI, coinfection with wild type (WT) and
spo0A mutant cells was done to determine the effect of sporulation on persistence (35). Since the
spo0A mutant does not produce spores, mice were infected with both WT and spo0A mutant cells
via oral gavage (35). At 2 to 8 days PI, significantly less spo0A mutant cell fecal shedding
occurred than WT, indicating that sporulation is important for persistence (35). The location at
which spores reside within the GI tract both during and after infection is not known but can
provide important insight into how spores persist.
Role of C. difficile Spores in Relapse
Not only do spores persist within the host but are important for disease relapse. In a
mouse model of CDI relapse, infection with the spo0A mutant, does not result in relapse of CDI,
unlike infection with a WT strain (35). In this murine model of CDI relapse, mice were infected
with either a WT or spo0A mutant strain and were given vancomycin 7 days PI, when symptoms
begin to decrease and subside. There was a rapid decease in fecal shedding that went below
detectable levels for both WT and sp0A mutant, due to the vancomycin treatment (35). However,
infection with a WT strain resulted in a significant increase in fecal shedding after stopping
vancomycin, indicative of relapse (35). This increase was not observed in mice infected with the
spo0A mutant (35). The mice were given multiple doses of vancomycin spread over a 100-day
period to induce multiple episodes of relapse (35). Only infection with the WT strain resulted in
an increase in fecal shedding every time vancomycin was stopped (35). In contrast, infection
with the spo0A mutant did not result in relapse (35). Collectively, these data suggest that cells
must be able to sporulate during antibiotic treatment to form spores that can persist and cause
relapse post-antibiotic treatment.
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Surface Layer Protein A
The surface layer (S-layer) is the outer most structure present on the surface of Gramnegative and Gram-positive bacteria that is composed of surface layer proteins (SLPs) (36). In
Gram-positive bacteria, the S-layer is attachment to the cell wall (36). There are multiple
functions for the S-layer including adhesion to environmental surfaces, interaction with
neighboring cells, and protection from lytic enzymes (37). Importantly, SLPs are the first point
of contact between the bacterial cell and the environment and serve to mediate this interaction.
An example of this includes SLPs of Bacillus cereus and Lactobacillus acidophilus, which
mediate adhesion to the GI tract mucosa and colonic epithelial cells, respectively (38, 39).
For C. difficile cells and spores to colonize and persist within the GI tract, they must
adhere to a luminally exposed surface within the large intestines. This adhesion for cells is likely
mediated by the S-layer. The S-layer of C. difficile is formed predominantly of SlpA and
paralogs of SlpA called cell wall proteins (CWPs) (Figure 3) (40, 41). These SLPs form a two
dimensional paracrystalline array that surrounds the surface of the entire cell (40). slpA is
translated to form a single pre-protein, which is transported out of the cell via an alternative Sec
secretion system, and modified by a cleavage event (40, 36). A protease (CWP84) cleaves the
SlpA pre-protein into two subunits, the high molecular weight (HMW) subunit and a low
molecular weight (LMW) subunit (42, 43). The LMW and HMW subunits bind non-covalently
forming a single SlpA monomer that self-assembles into the S-layer and binds to the cell wall
non-covalently (40, 44). The LMW subunit is the outer most portion of the monomer, which is
exposed to the environment, and is anchored to the cell wall by the HMW subunit (Figure 3)
(40). The LMW subunit has high sequence variability across different C. difficile strains, which
can be an immune evasion strategy by the bacteria (72). However, the sequence of the HMW
subunit of SlpA is highly conserved across different strains, considering it serves a conserved
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function of anchoring SlpA to the cell wall (72). Even though the HMW subunit is more interior
than the LMW subunit, the HMW subunit is likely also exposed to the external environment,
given that anti-HMW antibodies are present in the serum of CDI patients (45). Since SlpA is the
major protein located on the surface of C. difficile cells, it likely mediates adhesion to the GI
tract mucosa.

Figure 3. Schematic of the C. difficile S-layer. The C. difficile S-layer is composed of cell wall
proteins (light-dark green and gray ovals) and SlpA, which is the main constituent. The LMW
SlpA subunit (pink ovals) points away from the cell and is anchored to the cell wall by the HMW
SlpA subunit (red ovals). The cell wall, which is composed of peptidoglycans (black arcs) and
wall polymers, attaches the S-layer to the cytoplasmic membrane. Schematic hand drawn by
Margret Bradley (M.S.).

Not only is SlpA present on the surface of cells, but also spores. As preliminary data
leading up to this work, our lab found that SlpA is located on the surface of spores. By
performing immunofluorescence microscopy (IFM), using rabbit polyclonal anti-HMW SlpA
antibodies, we found SlpA localized to the surface of spores. We also performed mass
spectrometry on a coat protein extraction and found that SlpA is present in the extract. The coat
protein extraction was expected to contain spore surface associated proteins and coat proteins.
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Since SlpA is not a coat protein, but rather a vegetative cell S-layer protein, the presence of SlpA
in the extract suggests that SlpA is associated with the surface of the spore. We believe that SlpA
on the surface of spores comes from lysed cellular debris, which is a product of sporulation
(Figure 4). During sporulation, the mother cell lyses as the endospore emerges. The S-layer of
the lysed cell can provide a reservoir of SlpA that accrues on the surface of a newly formed
spore. Interestingly, our lab has found that the surface of in vitro C. difficile biofilm spore is
encased with a shroud-like structure (46). Using transmission electron microscopy (TEM), we
found that this structure is composed of thin fibers and densely stained granules, which
resembles lysed cellular debris (46). Since this structure is not present on the surface of spores
until the spore emerges from the mother cell, it is not a part of the coat (46). These data indicate
that the shroud structure is likely lysed cellular debris, containing SlpA, which encases the spore
once it emerges from the mother cell (46). It is not known whether the association of S-layer
proteins to the spore surface occurs in other sporulating species, except for Bacillus anthracis. In
B. anthracis, the cell S-layer protein (EA1) is present on the surface of spores (47). Therefore,
the association of S-layer proteins to the surface of spores is not unprecedented. However, little
is known about this association.
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Figure 4. Model Depicting SlpA Association with C. difficile Spore Surface. As the C.
difficile cell is ready to undergo sporulation, SlpA is located within the S-layer of the mother cell
and is not on the surface of the endospore. After sporulation, the spore emerges and the mother
cell lysis. SlpA from the S-layer of the lysed mother cell accumulates on the surface of the spore.
Role of SlpA in Adhesion
Even though we do not know the role of SlpA in pathogenesis, we know that SlpA
mediates adhesion to GI tract surfaces, including intestinal epithelial cells and ECM
glycoproteins. Binding of recombinant SlpA and native SLPs (S-layer extracted from cells) to ex
vivo human GI tissue has been demonstrated (48). In this study, when observing the GI tissue
sections, binding of recombinant SlpA and native SLPs occurred at the apical edge of gastric
epithelial ridges (48). Since the mucus layer, which rests on top of the epithelium, was not
preserved in these tissue sections, binding of SlpA to mucus was not observable (48). Also, in
this study, binding of recombinant HMW SlpA subunit and native SLPs to human epithelial cells
was also demonstrated in vitro (48). Another study has demonstrated that incubating C. difficile
cells with either anti-LMW SlpA antibodies or anti-HMW antibodies blocked adhesion of C.
difficile cells to colonic epithelial cells in vitro. Collectively, these data indicate that SlpA on the
surface of C. difficile cells contributes to adhesion to colonic epithelia. Not only can SlpA bind to
intestinal epithelial cells, but also to ECM glycoproteins as well. In vitro assays have
demonstrated that recombinant HMW SlpA subunit and native SLPs can bind collagen I,
thrombospondin, and vitronectin (48). These data indicate, that SlpA mediates adhesion of C.
difficile to parts of the GI tract mucosa. However, SlpA adhesion to the mucus specifically has
not been examined. Since SlpA is present on the surface of both C. difficile cells and spores and
mediates adhesion to parts of the mucosa in vito, it likely has a role in colonization during
infection and persistence after infection in vivo.
To elucidate the role of SlpA in colonization and persistence, a slpA genetic mutant is
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required. For many years, it was thought that a slpA mutant was non-viable. However, in a recent
publication, a viable slpA mutant was isolated (1). The authors confirmed that the mutant had
both the LMW and HMW SlpA subunits missing from the surface of cells (1). It was expected
that if SlpA mediates adhesion to the GI tract mucosa, then infection with the slpA mutant would
lead to a defect in colonization and persistence within the colon and cecum. In contrast to this
expectation, infection with a slpA mutant resulted in persistence of cells and spores within the
colon and cecum 14 days PI in their hamster model of CDI (1). Interestingly, infection with the
slpA mutant resulted in complete loss of virulence (1). In vitro characterization of the mutant
revealed a severe sporulation defect, reduced toxin production, and susceptibility to lysozyme
and human antimicrobial peptide (1). Even though toxin production and sporulation networks are
connected through regulators, such as RstA (regulator of sporulation and toxins), there is no
known connection between S-layer and toxin or sporulation networks (49, 50). Therefore, it is
unclear how point mutations in the slpA gene can result in defects in sporulation and toxin
production. None the less, these data indicate that the slpA gene mutation not only changes the
surface layer but is affecting other cellular mechanisms as well that might affect persistence.
C. difficile Surface Proteins Mediating Adhesion to Mucin
Even though there is no finding, to date, that suggests a role of SlpA in mediating
adhesion to mucin, there are other proteins that have been implicated in mediating C. difficile
cell adhesion to mucin. A study has demonstrated that recombinant flagellin (FliC) and flagellar
cap (FliD) proteins, as well as crude flagella, bind to cecal mucus isolated from mice (51). To
assess the role of the flagella in colonization in this study, mice were infected with either
flagellated or non-flagellated strains. C. difficile association with cecal mucosal tissue was
determined by isolating the cecum, removing the intestinal content, homogenizing the tissue, and
plating to obtain CFUs (51). Flagellar mutants were not used in this study due to the lack of
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genetic tools at the time (51). The flagellated strains associated more to mucosal tissue than the
non-flagellated strains, indicating a role for flagella in adhesion to the mucosa in vivo. The role
of the flagella in colonization and adhesion to colonic epithelial cells, but not specifically to
mucus, has been studied by other groups (25). However, the findings remain inconclusive and
vary depending on the strain used (25).
There are C. difficile spore surface proteins that mediate adhesion to mucin as well. Preincubating spores with polyclonal antibodies against the carboxyl-terminal of Toxin A disrupted
spore adhesion to mucin in vitro (52). These anti-Toxin A antibodies were found to cross-react
with a spore surface protein, CdeC (52). Not only has CdeC been implicated in mediating
adhesion of spores to mucus, but also another spore surface protein, CotE (53). Spores that were
either pre-incubated with anti-CotE antibodies or had a mutated cotE gene bound significantly
less to mucin than compared to untreated or WT spores, respectively (53). Interestingly, infecting
mice with a cotE mutant strain resulted in a requirement for a higher dose of spores than WT to
casue infection and colonization (53). The authors propose that spore surface proteins, including
CotE, promote colonization of the host by mediating adhesion to the mucus layer (53).
Collectively, we see that C. difficile spores bind to the mucus layer in vitro, and that this
adhesion is dependent on proteins located on the surface of both cells and spores. Even though
SlpA is a spore surface associated protein, we do not know whether SlpA mediates adhesion of
spores to mucin.
C. difficile Biofilms
Bacterial biofilms are an organized collection of cells, often encased in ECM composed
of polysaccharides, proteins, and/or extracellular DNA, that may, or may not, be attached to a
biotic or abiotic surface (46). The role of biofilms in persistent and recurrent disease is well
documented, especially in recurrent lung infections caused by Pseudomonas aeruginosa and
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urogenital infection caused by Escherichia coli (46, 54, 55). Biofilms facilitate persistence in
diverse ways, including adherence to host surfaces, evasion of the host immune system, and
resistance to antibiotic treatment (46, 54, 55). In the case of sporulating species, such as Bacillus
subtilis, biofilm formation results in production of spores (56). Spore production within a biofilm
can contribute to persistence of the biofilm, and therefore, can cause relapse. C. difficile is also
able to form biofilms in vitro. However, the role of C. difficile biofilms in disease or relapse is
not well elucidated. Interestingly, in vitro characterization of C. difficile biofilms revealed that
spore production does occur within biofilms and that cells within the biofilm are 100-fold more
resistant to metronidazole compared to cells grown in liquid culture (46). These data indicate that
C. difficile biofilms are in many ways similar to other bacterial biofilms and, therefore, the
ability to form a biofilm can cause persistence and relapse.
Since C. difficile biofilms can lead to persistence of cells and spores within the GI tract,
they have the potential to cause relapse of CDI. Therefore, in vivo characterization of C. difficile
biofilms is important in understanding relapse. In a recent study, infection with a variety of
individual C. difficile isolates in a mouse model, resulted in individual cells dispersed within the
mucus layer in the large intestines during infection (7 days PI) (27). However, infection with the
R20291 epidemic strain resulted in cells that were in aggregates located within the mucus layer
(27). Immunochemical analysis of these aggregates demonstrated that the cells are incased in a
biofilm-like matrix (27). These results indicate that individual C. difficile cells, depending on the
strain, can either form aggregates in vivo, similar to what occurs in a biofilm, or can be dispersed
throughout the mucus layer (27). However, it is not known whether these cellular distribution
patterns change or stay consistent during the course of infection and after infection. If it is the
case that cells have an aggregate, biofilm-like cellular distribution within the mucus layer at late
time points during infection, then a biofilm-like structure would allow for persistence within the
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GI tract even after disease symptoms have resolved. Importantly, whether C. difficile spores are
present within the biofilm-like structures in vivo is not known. However, determining the
location and distribution of spores during and after infection is important in understanding
relapse.

CHAPTER TWO
MATERIALS AND METHODS
C. difficile Culture
Frozen stock of C. difficile BI17/NAP1/027 (Hines VA, Maywood, Illinois), containing
15% glycerol in tryptic soy broth (TSB), was streaked onto a pre-reduced blood agar plate
(Columbia Agar with 5% sheep blood). The plate was incubated at 37ºC for 48 hours in an
anerobic chamber (80% N2, 15% CO2, and 5% H2). From the plate, a single colony was used to
inoculate 15mL of TSB or brain heart infusion (BHI) liquid media, which was incubated at 37ºC
overnight (16-20 hours) or for 24 hours.
C. difficile Mouse Model of Infection
CDI mouse model was followed according to an established protocol (57). C57BL/6 male
mice (Jackson Laboratory) were housed at the Comparative Medicine Facility at Loyola
University Chicago until 8-12 weeks of age. Mice were administered antibiotics in sterile
drinking water for 72 hours and then sterile drinking water without antibiotics for 48 hours. The
following were the antibiotics and concentrations: vancomycin (0.045 mg/mL), metronidazole
(0.215 mg/mL), gentamicin (0.035 mg/mL), kanamycin (0.4 mg/mL), and colistin (850 U/mL).
An intraperitoneal injection of clindamycin (10mg/kg of body weight) was administered 24
hours before infection. Mice were administered 105 spores of epidemic C. difficile strain
BI17/NAP1/027. Physical symptoms of infection (weight loss, wet tail, lethargy, and diarrhea)
were monitored. Mice were euthanized by carbon dioxide asphyxiation, followed by cervical
dislocation. Subsequently, the cecum and colon were isolated with retention of intestinal
20
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contents. Tissue was collected for microscopy and fixed in Carnoy fixative (60% ethanol, 10%
acetic acid, 30% chloroform) and the rest of the tissue was not placed in fixative and used for
spore quantification. Mice were sacrificed at time points during infection (2, 4, 6, 8, 10 days PI)
when physical symptoms of infection were present, and after infection (15, 20, 25, 40 days PI)
when physical symptoms of infection were not present. Mice that were not infected and not
antibiotic treated, as well as mice that were not infected and antibiotic treated were used as
controls. Control mice were housed in separate cages, but at the same location as the infected
mice. BI-17 spores used to infect mice were produced in an anaerobic chamber by picking a
single colony from a blood agar plate, inoculating 15mL BHI liquid media, and incubating the
media at 37ºC overnight. From the overnight culture, 250µL were spread on a blood agar plate
and the plates were incubated at 37ºC for 4-7 days. To collect the spores, 10mL of PBS was
added to each plate and the surface of the plate was disturbed using a plate spreader. The spores
were collected in a 15mL conical tube, washed once in PBS, by centrifuging at 6000rpm for 10
minutes, and the supernatant was removed. Spores were resuspended in PBS and stored at 4ºC.
Histology
The cecum and colon were removed from Carnoy fixative and placed in sterile petri
dishes. Two pieces of tissue from the cecum and two pieces from the proximal, medial, and
distal colon were cut in cross-section. All tissue sections were placed into histology tissue
cassettes, paraffin embedded without formalin, cut into 3.5µm thick longitudinal sections, and
placed onto glass slides for microscopy. Each slide had two pieces of tissue from one location.
The epithelial layer was stained using hematoxylin and eosin stain (H&E) and the mucin layers
were stained with Alcian blue stain. Before applying any staining, FISH, or IFM protocol, the
tissue sections were first deparaffinized. Deparaffinization of the tissue sections was done by
placing slides in a slide container that had the following solutions, gently shaking the container
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side-to-side for the following number of times, pouring out the solution, and adding the next
solution in sequence: xylenes (15 times), 100% ethanol (30 times), 95% ethanol/distilled water
solution (40 times), and 75% ethanol/distilled water solution (40 times). Slides were placed in a
50% ethanol/distilled water solution for 2 minutes without shaking and then in water only while
shaking side-to-side 20 times. For the Alcian blue staining protocol, 100µL of Alcian blue stain
was applied to each slide for 5 minutes. Slides were rinsed with distilled water and analyzed with
a light microscope at 400X magnification. H&E stained slides were also analyzed with a light
microscope at 200X magnification. Paraffin embedding, tissue-block sectioning, and H&E
staining was performed by the Tissue Processing Facility at Loyola University Chicago.
FISH and IFM Analysis of Tissue Sections
After deparaffinizing and circling the tissue sections with a hydrophobic pen, each tissue
section was treated with 100µg/mL lysozyme and 20U mutanolysin in STE buffer (10mM Tris
pH 7.4, 1mM EDTA, and 96mM NaCl). The slides were incubated at 37ºC for 1 hour and
washed 3 times in PBS and once in 100% ethanol. Each wash step entailed pouring liquid into
the slide container, leaving the slides submerged in liquid for 10 minutes at room temperature,
and pouring the liquid out. Adhesive in situ hybridization chambers (Bio-Rad Laboratories) were
placed on the glass slide around the tissue sections. FISH probe hybridization solution (20mM
Tris pH 7.4, 0.9M NaCl, 0.01% SDS) was preincubated at 50ºC and 65µL of the solution was
mixed with 100ng of the CD198A probe (C. difficile 16S rRNA specific sequence conjugated to
Alexa Fluor 488 (5’-/5Alex488N/CAT CCT GTA CTG GCT CAC-3’)) (Integrated DNA
Technologies) in the dark and added to each slide. After placing the hybridization chamber
coverslips on each slide, the slides were incubated at 50ºC overnight in the dark on the slidemount apparatus. The following day, the chamber cover slips were removed, and the slides
remained in the dark for the rest of the protocol. The slides were placed into a slide container and

23
washed three times with preincubated (50ºC) washing solution (0.2M Tris pH 7.4, 0.9M NaCl).
Each wash step entailed pouring the wash solution into the slide container, leaving the slides
submerged for 10 minutes at 50ºC, and pouring the wash solution out.
Immediately following the FISH protocol, the IFM protocol was performed. The slides
remained in the dark throughout this protocol. After circling the tissue sections with a
hydrophobic pen, 100µL of blocking solution (0.02g/mL BSA in PBS and 70µL/mL sheep
serum) was added to each slide. Slides were incubated at room temperature for 1 hour. After
removing the blocking solution, 100µL of polyclonal rabbit anti-HMW SlpA antibody serum
(Katherine L. Knight Laboratory, Loyola University Chicago) at a dilution of 1:20 in PBS
containing 2% BSA was added to slides and the slides were incubated at 37ºC for 1 hour. Slides
were placed in the slide container and washed 3 times with PBS containing 0.1% Tween-20.
Each wash step entailed pouring the solution into the slide container, leaving the slides
submerged for 10 minutes at room temperature and pouring the wash solution out. Secondary
antibody Alexa Fluor 594 goat anti-rabbit IgG (Cell Signaling Technologies) was diluted at
1:500 with PBS containing 2% BSA and 100µL was added to slides. The slides were incubated
at 37ºC for 1 hour. Slides were placed in the slide container and washed 3 times with PBS
containing 0.1% Tween-20, as previously stated. To sterile distilled water, 0.1% of the Hoechst
33342 stain (Thermo Fisher Scientific) was added and 100µL of this solution was added to
slides. Slides were incubated for 5 minutes at room temperature. After dipping the slides in
sterile distilled water and suctioning off the excess fluid, the tissue sections were covered with
PermaFluor Aqueous Mounting Medium (Thermo Fisher Scientific), covered with glass
coverslips, and stored at 4ºC.
Fluorescence microscopy analysis was performed using the LSM 510 laser scanning
confocal microscope (Carl Zeiss Inc.). The oil emersion 63X objective lens was used to examine
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all sections. The CD198A probe was detected using the Argon/2 laser and the AF488 filter and
the Alexa Fluor 594 secondary antibody was detected using the DPSS (561-10) laser and the
Rhod filter. The Hoechst 33342 stain was detected using the Diode (405-30) laser and the DAPI
filter. The confocal parameters (pinhole, optical slice, offset) remained approximately the same
across all sections, except the detector gain. Across most sections, the detector gain parameter
was set between a range of 568-590. This range was determined by applying the SlpA preimmune serum to infected tissue sections and eliminating the fluorescence when acquiring the
image because this fluorescence was considered as background. For infected tissue sections that
were treated with anti-HMW SlpA antibodies, the gain was generally set within this range,
depending on fluorescence of the background (noise) relative to fluorescence of spore shaped
objects (signal), as observed through the eyepiece.
The polyclonal rabbit anti-HMW SlpA antibody serum was obtained from Dr. Katherine
L. Knight’s Laboratory at Loyola University Chicago. Briefly, the slpA gene (region coding for
the HMW subunit ) from C. difficile 630 strain was inserted into an expression plasmid and
transformed into Escherichia coli strain via electroporation. HMW SlpA target protein was
purified using column chromatography from target clones and was used to immunize 3 month
old New Zealand White rabbits. Rabbits were immunized with adjuvant via intramuscular and
subcutaneous injections. The rabbits were boosted every 2 weeks with the HMW SlpA antigen
with adjuvant and blood was collected every 2 weeks throughout the immunization process to
collect serum. The HMW SlpA antigen specific titers were determined via enzyme-linked
immunosorbent assay.
C. difficile Spore Quantification Within Mouse Large Intestine
To quantify spores in the luminal content, the cecum and colon tissue of infected mice
was harvested during (2, 4, 6, 8,10 days PI) and after infection (15, 20, 25, 40 days PI). The
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tissue was cut open from one side and gentle pressure, using a 1mL pipet tip, was applied to the
tissue to squeeze out the luminal contents from the opening of the tissue into a 2mL tube. The
fraction was diluted in PBS to a total volume of 1mL and heat shocked at 65ºC for 30 minutes.
After performing serial dilutions, the fraction was plated on pre-reduced TCCFA plates (9.4g/L
Na2HPO4, 1.0g/L KH2PO4, 2.0g/L NaCl, 0.12 g/L MgSO4, 6.0 g/L fructose, 1.0 g/L sodium
taurocholate, 50.0 g/L proteose peptone, 0.25% neutral red solution (0.33%), agar, 0.25 mg/mL
Cycloserine, and 0.008 mg/mL Cefoxitin). The plates were incubated at 37ºC for 24-48 hours
anaerobically and CFUs were counted. Once the luminal content was removed, the rest of the
tissue was used to quantify spores associated with the mucosa. The tissue was placed in a sterile
petri dish and cut open to exposing the lumen. The tissue was rinsed 5 times with 1mL PBS. To
do the washes, the petri dish was tilted to one side so that the PBS which contacted the tissue
does not make contact with the tissue again. After the washes, the tissue was placed in a 2mL
tube and PBS was added for a total volume of 1mL. The tissue was sonicated (pulse cycle 30,
output 5) for a total of 5 rounds (1 minute per round), while resting on ice for 1 minute between
rounds. The fraction was heat shocked (65ºC for 30 minutes), serial diluted, and plated on prereduced TCCFA plates. The plates were incubated at 37ºC for 24-48 hours anaerobically and
CFUs were counted.
IFM Analysis of C. difficile Biofilm and Liquid Culture
In vitro 14 day biofilms were taken out of the anaerobic chamber and scraped off the
polycarbonate filters, using a 1mL sterile pipet tip, into a 2mL tube containing PBS. A 24-hour
liquid culture, grown in TSB, was taken out of the anaerobic chamber and centrifuged at
6,000rpm for 10 minutes. The supernatant was removed, and the pellet was suspended in PBS.
IFM as performed on both the biofilm and liquid culture suspensions. Multi-well slide was
coated with sterile distilled water containing 0.01% poly-L-lysine by adding this solution to
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wells and washing the well twice with sterile distilled water. Each wash was done by adding
10µL of water to wells and suctioning out the liquid. 10µL of each of the biofilm and liquid
culture suspensions was added to the wells and left at room temperature for 10 minutes. The
wells were washed 3 times in PBS and were left to air dry for 1 hour at room temperature. The
wells were rehydrated by adding PBS and leaving it in the wells for 3 minutes, and subsequently,
suctioning out the liquid and washing once with PBS. 10µL of blocking solution (PBS
containing 2% BSA) was added to wells, which were incubated at room temperature for 30
minutes. After suctioning out the blocking solution, the wells were washed once in PBS. AntiHMW SlpA antibody serum or HMW SlpA pre-immune serum was diluted (1:30) in PBS
containing 2% BSA and 10µL of this solution was added to wells. The wells were incubated for
1 hour at 37ºC. After washing wells 3 times with PBS, secondary antibodies including either
Alexa Fluor 594 goat anti-rabbit IgG (Cell Signaling Technologies) or Alexa Fluor 488 goat antirabbit IgG (Thermo Fisher Scientific) were suspended in PBS containing 2% BSA at a dilution
of 1:200 or 1:300, respectively. 10µL of the secondary antibody solution was added to wells and
incubated at 37ºC for 1 hour in the dark. Wells were kept in the dark after this point and washed
9 times in PBS. PermaFluor Aqueous Mounting Medium (Thermo Fisher Scientific) was added
to each well, wells were covered with glass coverslips, and stored at 4ºC.
C. difficile Biofilm Cultivation
A single colony from a blood agar plate was used to inoculate 15mL TSB in an anaerobic
chamber. The inoculated TSB was incubated at 37ºC overnight (to an optical density of 0.8).
1mL of the culture was centrifuged (table-top centrifuge) for 5 minutes and the pellet was
resuspended in 2mL TSB. 10µL of this culture was used to inoculate pre-sterilized polycarbonate
membrane filters (0.2µm pore size, 25mm diameter) (Millipore Sigma), which were placed on
TSB agar plates. The plates were incubated at 37ºC for 3-4 days. After 3-4 days, the filters were
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transferred to fresh TSB agar plates. The biofilms were grown on the filters for a total of 14 days.
To collect the biofilms, a 1mL sterile pipet tip was used to scrape off the biofilm from the filters
into PBS. Biofilms in PBS were kept in aerobic conditions at 4ºC until use, killing vegetative
cells. To quantify the number of spores in the biofilm, the biofilm suspension was serial diluted,
plated on pre-reduced BHI-T agar plates (containing 1% sodium taurocholate), and incubated
anaerobically at 37ºC for 24 hours.
Mechanical and Biochemical Treatments of C. difficile Biofilms
In vitro 14 day biofilm suspensions were subjected to mechanical and biochemical
treatments to remove SlpA off the surface of spores. One mechanical treatment entailed washing
the biofilm suspension with PBS 10 times. A single wash included vortex of the suspension for 1
minute, centrifuging for 10 minutes at 10,000rpm, removing the supernatant, and resuspending in
PBS. Another mechanical treatment entailed sonication of the biofilm suspension in buffered
solution. The biofilm was suspended in a buffered solution (50 mM Tris/HCl and 0.5 mM EDTA
pH 7.5) and sonicated (pulse cycle 30, output 5) for 10, 1 minute bursts, while cooling on ice for
2 minutes between bursts (34).
A biochemical treatment entailed washing the 14 day biofilm suspension in the following
solutions, sequentially: (1) 0.5M KCl, 1% glycerol, 0.02M Tris, 0.004M EDTA solution, (2) 1M
NaCl solution, (3) 0.05% SDS solution, (4) 0.05M Tris, 0.01M EDTA pH 8 solution, and (5)
0.05% Tween-20, 0.005 M EDTA solution. After suspending the biofilm in one of the solutions,
the suspension was vortexed for 1 minute and centrifuged for 5 minutes at 6,000 rpm. The
supernatant was removed, and the pellet was suspended in the next solution, in order. After
performing a wash with the last solution, the pellet was washed 3 times in sterile distilled water.
A variation of this protocol was performed where the protocol was performed as stated, except
that the salt concentration in solutions (1) and (2) was increased to 3.5 M KCl and 4 M NaCl,
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respectively. Another variation of this protocol was performed where the protocol was performed
as stated, except that the salt concentration in solutions (1) and (2) was increased to 3.5 M KCl
and 4 M NaCl, respectively, and the detergent concentration in solutions (3) and (5) was
increased to 5% SDS and 5% Tween-20, respectively. A separate biochemical treatment was
performed where the biofilm was suspended in Proteinase K and Sarcosyl solution (0.3mg/mL
Proteinase K, 1% Sarcosyl, 125mM Tris, 200mM EDTA) and incubated at 37ºC with gentle
shaking for 2 hours (58, 59). The suspension was washed 10 times in PBS with one wash
entailing centrifugation at 10,000rpm for 5 minutes, removal of supernatant, addition of PBS,
and vortex for 1 minute. A variation of this protocol was performed where the protocol was
performed as stated, except that the Proteinase K and Sarcosyl concentrations were increased to
1mg/mL and 10%, respectively. As a positive control, a treatment known to remove the spore
coat was also performed. The biofilm suspension was combined with 13µL of Laemmli buffer
(63mM Tris pH 6.8, 10% glycerol, 2% SDS) and 1.5µl of 1M DTT. The suspension was
vortexed and incubated at 100ºC for 5 minutes, followed by 1 minute of vortex and re-incubation
at 100ºC for 5 minutes. After the 1 minute of vortex, the suspension was centrifuged at
10,000rpm for 5 minutes and the supernatant was removed.
Mucin Adhesion Assay Utilizing Mucin-Agar Gel
The following protocol was modified from an established protocol utilizing mucin-agar
gels (60, 61). To prepare the mucin-agar gels, mucin from porcine stomach, either Type II (crude
powder preparation) (Millipore Sigma) or Type III (partially purified powder preparation)
(Millipore Sigma), was mixed with agar (10% mucin, 2% agar) in sterile distilled water. The
mixture was autoclaved (15 minutes, liquid cycle) and 150µL was aliquoted into 2mL tubes.
After the mucin-agar gels solidified, they were placed at 4ºC until use. The following gels were
also made in sterile distilled water: agar (2%), agarose (2%), and gelatin (10%). For mucin-agar
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and agar gels that were blocked, the gels were incubated with PBS containing 2% or 10% BSA
for 120 minutes at either room temperature or 37ºC. After removing the blocking solution form
gels that were blocked, 500µL of 14 day biofilm suspension was added to gels that were then
incubated at 37ºC for 90 minutes. As a control for the total number of spores added to the assay,
the biofilm suspension was added to the mucin-agar gel. The unbound spores were removed by
performing 3 washes with PBS, except for the control gels. Each wash entailed adding 1mL of
PBS to gels and removing all PBS from the gel surface. 1mL of PBS containing 0.1% Triton-X
100 was added to gels, including control gels. The tubes containing the gels were vortexed for 2
minutes and incubated at 37ºC for 30 minutes. The liquid in the tubes was serial diluted using
PBS and plated on pre-reduced BHI-T agar plates. The plates were incubated anaerobically at
37ºC for 24 hours and the colony forming units were counted. Percent adhesion was calculated
by calculating CFUs of bound spores, divided by CFUs of the total number of spores added to
the assay (control), multiplied by 100.
Mucin Adhesion Assay Utilizing Mucin Coated Microtiter Well
The following protocol was modified from an established protocol utilizing mucin-coated
wells (23). To a 96-well microtiter plate with MaxiSorp coating (Thermo Fisher Scientific),
100µL of PBS containing 40mg/mL of mucin from porcine stomach, either Type II (crude
powder preparation) (Millipore Sigma) or Type III (partially purified powder preparation)
(Millipore Sigma) was added to each well. The plate was incubated at 4ºC overnight with gentle
rotation. Wells were also incubated with PBS only (no mucin) as control. The plate was
sterilized using ultraviolet germicidal irradiation the following day and placed in the anaerobic
chamber overnight. The next day, the mucin solution was removed, and the wells were washed 3
times with PBS by adding 100µL PBS and removing all liquid from wells. Then, approximately
1x107 CFUs of 14 day biofilm spores were incubated with anti-HMW SlpA antibody serum at a
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dilution of 1:10, 1:100, and 1:1000 in 1mL PBS. Serum from naïve rabbit at 1:100 dilution and
PBS only (no serum) was added to spores, as controls. All suspensions were incubated at 37ºC
for 30 minutes. Suspensions were centrifuged at 10,000rpm for 10 minutes and 900µL of the
supernatant was removed, without disturbing the pellet. 900µL of PBS was added and the
suspensions were centrifuged again. 900µL of the supernatant was removed and approximately
5x106 CFUs of spores were added to wells. PBS was added to wells for a total volume of
250µL/well. As a control for the total number of spores added to the wells, spores that were
incubated with PBS only (no serum) were added to wells that were incubated in PBS only (no
mucin). PBS was added to these wells for a total volume of 150µL/well. The plate was incubated
anaerobically at 37ºC for 90 minutes. Wells were washed 3 times with PBS, except for control
wells. One wash included, removing 100µL of liquid, adding 100µL of PBS, pipetting in-and-out
3 times slowly, and removing 100uL. As a result, a 150uL liquid buffer was maintained inside
the wells throughout the wash step. 100uL of 1.5% Triton-X 100 was added to all wells,
including control wells, resulting in 250µL of liquid in all wells. The plate was incubated at 37ºC
for 30 minutes. The liquid inside the wells was serial diluted, using PBS, and plated on prereduced BHI-T agar plates. The plates were incubated at 37ºC for 24 hours and the CFUs were
counted. Percent adhesion was calculated by calculating CFUs of bound spores, divided by
CFUs of the total number of spores added to the assay (control), multiplied by 100.

CHAPTER THREE
EXPERIMENTAL RESULTS
Localization and Quantification of C. difficile Spores Within the Mouse Cecum and Colon
During and After Infection
Introduction
A potential cause of recurrence is the persistence of C. difficile spores within the GI tract.
C. difficile spores persist within the GI tract after infection, but the location at which they reside
is not known (29, 30, 35). Identifying the location at which spores reside within the cecum or
colon can help us identify where spores might adhere to persist. If spores reside within the outer
mucus layer, like vegetative cells during infection, then they have the potential to adhere to
mucin during infection and persist after infection (6). By binding to mucin during infection, a
reservoir of spores can continue to persist after infection. This reservoir of spores within the
outer mucus layer can germinate to form vegetative cells that can cause CDI relapse. Therefore, I
tested the hypothesis that spores reside within the outer mucus layer in the cecum and colon both
during and after infection.
To test this hypothesis, I employed an established mouse model of CDI (57). Briefly,
mice were pretreated with an antibiotic cocktail and challenged with 105 spores of epidemic C.
difficile BI-17 strain via oral gavage. The cecal and colonic tissue were harvested at various time
points both during and after infection, fixed with Carnoy’s fixative, paraffin embedded, and
sectioned for microscopy. I used IFM to identify the location of C. difficile spores and
fluorescence staining to identify the location of the outer mucus layer. Based on our previous
31
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work, we know that SlpA is present on the surface of C. difficile spores cultured in vitro, by
performing IFM, using anti-HMW SlpA antibodies. To detect C. difficile spores in cecal and
colonic tissue sections, I performed IFM, using anti-HMW SlpA antibodies. I expected that the
anti-HMW SlpA antibodies will detect both C. difficile cells and spores within the outer mucus
layer in the cecum and colon both during and after infection. To differentiate between cells and
spores, I relied on morphological differences between the two cell types. Since it is well
established that CDI results in disruption of the mucosa during infection, I examined the
structure of the epithelium and mucus layer, as a control, to determine how these layers change
throughout and after infection. I examined the structure of the epithelium, using hematoxylin and
eosin (H&E) stain, and the mucus layer, using Alcian blue staining.
As a quantitative assessment to test whether spores reside within a specific niche to
persist and whether this location changes throughout and after infection, I quantified C. difficile
spores within the lumen and mucosa of the cecum and colon both during and after infection. To
determine the location of this potential spore reservoir, I harvested a luminal fraction, which is
the intestinal content from the cecum and colon, and a mucosal fraction, which is the remaining
tissue after the intestinal content is removed. These fractions were heated to eliminate C. difficile
vegetative cells and plated on C. difficile selective plates to numerate C. difficile spores.
Locating SlpA On the Surface of C. difficile Spores Cultured In Vitro
As preliminary data leading to this work, we found that SlpA is present on the surface of
C. difficile spores cultured in vitro. A former Post-Doctoral Fellow from our laboratory,
Ekaterina Semenyuk, demonstrated that SlpA is present on the surface of spores from a 24-hour
liquid culture, by performing IFM, using polyclonal rabbit anti-HMW SlpA antibody serum. The
24-hour liquid culture was prepared by inoculating and incubating liquid media for 24 hours,
which resulted in the presence of both cells and spores in the liquid media. To detect spores from
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the liquid culture, phase-contrast microscopy was utilized (Figure 5A, C). The IFM data reveled
that anti-HMW SlpA antibodies were bound to the surface of spores and cells, indicating the
presence of SlpA on the surface of both cell types (Figure 5B). To test the specificity of the antiHMW SlpA antibody serum, the HMW SlpA pre-immune serum was applied to the 24-hour
liquid culture. The antibodies in the pre-immune serum did not bind to the spores or cells, as
expected (Figure 5D). Spores from an in vitro C. difficile biofilm also had SlpA on the surface.
After growing the in vitro biofilm for 14 days, I performed IFM, using anti-HMW SlpA
antibodies. Spores were detected within the biofilm using phase-contrast microscopy (Figure 5E,
G). The anti-HMW SlpA antibodies detected SlpA on the surface of spores, and the HMW SlpA
pre-immune serum did not bind to the spores (Figure 5F, H). These data demonstrate that spores
within a C. difficile biofilm also have surface associated SlpA.
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Figure 5. IFM Analysis of C. difficile Cultured In vitro. C. difficile 24-hour liquid culture was
fixed onto a slide and treated with either anti-HMW SlpA antibody serum (B) or HMW SlpA
pre-immune serum (D). C. difficile 14 day in vitro biofilm was fixed onto a slide and treated with
either anti-HMW SlpA antibody serum (F) or HMW SlpA pre-immune serum (H). Phasecontrast images were obtained for the representative fluorescent images (A, C, E, and G). White
arrows are pointing to spores in the phase-contrast images and the respective fluorescent images.
Structural Characterization of Cecal and Colonic Mucosa During and After Infection
Since CDI leads to the disruption of the mucosal barrier, I characterized the structural
organization of the epithelium and the mucus layer during and after infection. It is well
established that the mucosa is largely disrupted during infection. Published data from our
laboratory demonstrate, using H&E staining, that inflammation, edema, epithelial damage, and
immune cell infiltration occurs in and around the epithelium at 2 and 4 days PI in the cecum and
colon (6). As part of this work, the mucus layer was also examined in these sections by
performing light microscopy, using Alcian blue staining, and IFM, using mucin specific
antibodies. However, the focus of this work was not to determine the structural changes of the
mucus layer over the course of infection. Therefore, we do not know how the epithelium is
organized after infection and how the mucus layer is organized during and after infection.
Structural insight to how the mucosa is organized throughout and after infection will help
characterize the location where spores and cells may reside.
To examine the epithelial layer, H&E staining was performed on cecal and colonic tissue
sections at time points during infection (2 and 6 days PI), and after infection (15 and 40 days PI).
The sections were examined under light microscopy and I expected epithelial cells to stain a
blue-purple color, immune cells to stain a blue-red color, and goblet cells to remain colorless.
Epithelial damage and immune cell infiltration were observable in the cecum and colon at 2 and
6 days PI (Figure 6A-D). At 15 and 40 days PI, the organization of the epithelium in the cecum
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and colon was similar to the controls, which were sections from uninfected antibiotic and
uninfected non-antibiotic treated mice (Figure 6E-L).
To examine the mucus layer, I performed Alcian blue staining on cecal and colonic tissue
sections at time points during and after active infection. The sections were examined using light
microscopy and I expected dense blue staining adjacent to the epithelium, which would likely be
the inner mucus layer and light blue-green staining adjacent to the inner mucus layer, which
would likely be the outer mucus layer. At 2 and 6 days PI, the inner mucus layer within the
cecum and colon is disrupted and not observable in some sections (Figure 7A-D). However, the
outer mucus layer is observable at 2 and 6 days PI (Figure 7A-D). At 15 and 40 days PI, the
organization of the mucus layers is similar to control tissue from mice that were uninfected
antibiotic and uninfected non-antibiotic treated (Figure7E-L).
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Figure 6. H&E Staining Analysis of Cecum and Colon Tissue During and After Infection.
Cecum and colon tissue were excised from mice during infection (A-D), after infection (E-H),
and from mice that were uninfected, non-antibiotic treated (-ABX) (I-J), and uninfected,
antibiotic treated (+ABX) (K-L). Tissue was paraffin embedded, sectioned onto slides and H&E
stained. Light microscopy was performed at 200X magnification. Yellow bracket indicates
location of the epithelium. Yellow arrow points to immune cells. Red arrow points to dislodged
pieces of epithelium.
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Figure 7. Alcian Blue Staining Analysis of Cecum and Colon Tissue During and After
Infection. Cecum and colon tissue were excised from mice during infection (A-D), after
infection (E-H), and from mice that were uninfected, non-antibiotic treated (-ABX) (I-J), and
uninfected antibiotic treated (+ABX) (K-L). Tissue was paraffin embedded, sectioned onto slides
and stained with Alcian blue. Light microscopy was performed at 400X magnification. “E”
indicates location of the epithelium. Red dashed line separates epithelium from the inner mucus
layer. “IML” and red bracket indicates location of inner mucus layer. “OML” indicates location
of outer mucus layer.
Locating C. difficile Spores Within the Mouse Cecum and Colon During and After
Infection
To locate C. difficile spores within the cecum and colon, I harvested the tissue from
infected mice during infection (2, 4, 6, 8, and 10 days PI) and after infection (15, 20, 25, 40 days
PI). Time points during infection were a period when mice exhibited physical symptoms of
disease, such as weight loss, wet tail, and lethargy. After infection was a period when mice did
not exhibit physical symptoms of disease and appeared to have recovered. The cecum and colon
were removed and fixed in Carnoy’s fixative, which preserves the tissue and mucus (62). Two
tissue segments were cut with retention of intestinal content from the cecum, and two tissue
segments from the proximal, medial, and distal colon. The segments were paraffin embedded and
cut onto slides for fluorescence microscopy. To detect C. difficile spores, immunofluorescence
protocol was performed on tissue slides, using anti-HMW SlpA antibodies. The anti-HMW SlpA
antibodies were expected to detect both C. difficile spores and cells, but the two were
differentiated based on their overall length and shape. Even though the length of a C. difficile
spore (1-3 µm) and cell (> 3.5 µm) varies depending on the strain, as well as intrastrain
differences, spores are elliptical in shape and have a shorter length than cells, which are rod
shaped and longer in length (63, 64). After the immunofluorescence protocol was performed,
using anti-HMW SlpA antibodies, tissue slides were treated with a DNA fluorescent stain. The
DNA stain was used to identify the location of the epithelium and the microbiota. Since the
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microbiota is located within the outer mucus layer, location of the microbiota was used as a
proxy for the location of the outer mucus layer. The inner mucus layer was not expected to be
stained because it is void of bacteria and therefore DNA.
As a negative control for the presence of C. difficile in cecal and colonic tissue, I applied
the anti-HMW SlpA antibodies to tissue sections from mice that were uninfected antibiotic
treated and uninfected non-antibiotic treated. I did not detect a high fluorescence signal from
spore or cell shaped objects (Figure 8K-N). However, a fluorescence signal was present, but
nearly all objects had similar levels of fluorescence intensity. I interpreted this signal as
background because when examining infected sections, using the anti-HMW SlpA antibodies, I
was able to detect a higher fluorescence signal from spore and cell shaped objects, relative to this
background for most tissue sections (Figure 8A-J and Figure 9A-H).
To test the specificity of the anti-HMW SlpA antibodies, I applied the HMW SlpA preimmune serum to infected cecal and colonic tissue sections (Figure 8S, T). I also applied the
HMW SlpA pre-immune serum to sections from mice uninfected antibiotic treated and
uninfected non-antibiotic treated (Figure 8O-R). For both the infected and uninfected antibiotic
and non-antibiotic treated sections, I did not detect a high fluorescence signal from spore or cell
shaped objects and background fluorescence was present, but almost uniform in intensity (Figure
8O-T). These data indicated that the anti-HMW SlpA serum contains antibodies that bind
specifically to spore and cell shaped objects and that these antibodies are absent in the preimmune serum, as expected.
When examining infected sections using the anti-HMW SlpA antibodies, I was able to
eliminate most, if not all, of the background when acquiring an image, using the confocal
microscope parameters. By adjusting the gain parameter, which is the signal to noise ratio, I
attempted to limit the background. I first determined what the gain parameter range would be
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when all background is eliminated when acquiring the image, by applying the pre-immune serum
to infected sections and eliminating all the fluorescence when acquiring the image. Then, I used
this gain parameter range, which was expected to eliminate all background fluorescence, on
infected sections treated with the anti-HMW SlpA antibodies to acquire an image. But, in some
sections, the fluorescence intensity of the background could not be eliminated entirely from
sections during and, particularly, after infection (Figure 8C, D and Figure 9E, F). I suspect that
the background fluorescence intensity could not be eliminated entirely because the gain
parameter range was slightly different for each section. Therefore, to determine if an ellipsoidshaped object is a spore and not background, I confirmed that the fluorescence of the object is
higher than background through the microscope eyepiece, and then acquired an image of the
object by adjusting the gain within a specific range to limit the background, without eliminating
the fluorescence of the spore shaped object. Using the stated method, I evaluated the relative
abundance of spore shaped objects as a qualitative assessment between two locations.
At early time points during infection (2, 4 days PI) within the cecum and colon, the
relative abundance of spore shaped objects was similar in the lumen and the mucosa. At late time
points during infection (6, 8, 10 days PI) within the cecum and colon, the relative abundance of
spore shaped objects was higher in the lumen than the mucosa. Within the mucosa, spore shaped
objects were found within the outer mucus layer and rarely found associated with the epithelium
or the inner mucus layer in the cecum and colon at all-time points during infection (Figure 8A-J).
There were more spore shaped objects observed in the outer mucus layer at early time points
during infection (2, 4, 6 days PI) than later time points (8, 10 days PI) (Figure 8A-F, G-J). No
observable difference was found in the relative abundance of spore shaped objects in the outer
mucus layer within the cecum or colon or within the three segments of the colon (proximal,
medial, distal). The cecum and colon of an average of three mice per time point were examined
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during infection. On average, for each of the time points, four tissue sections, each containing
two pieces of tissue were examined for the cecum and colon.
During all-time points after infection within the cecum and colon, more spore shaped
objects were present in the lumen than the mucosa. Within the mucosa, spores were located
within the outer mucus layer and were rarely associated with the epithelium or the inner mucus
layer (Figure 9A-H). Spores continued to persist within the outer mucus layer, even at 40 days PI
(Figure 9G-H). There was no observable difference in the relative abundance of spore shaped
objects within the outer mucus layer of the cecum or colon, or within the three segments of the
colon (proximal, medial, distal). The cecum and colon of an average of two mice per time point
were examined after infection. On average, for each of the time points, two tissue sections, each
containing two pieces of tissue were examined for the cecum and colon.
When comparing the relative abundance of spores in the outer mucus layer during and
after infection, there were more spore shaped objects during infection, particularly 2-6 days PI,
than at any time point after infection (Figure 8A-F, Figure 9A-H). Both during and after
infection, spore shaped objects were rarely observed in clumps or in close association to one
another. Rather, they were distributed separately throughout the outer mucus layer and not in
aggregates, indicating that spores are likely not in a biofilm-like setting.
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Figure 8. IFM Analysis of Cecum and Colon During Infection. Cecum and colon tissue were
excised from mice during infection at 2 (A-B, T), 4 (C-D), 6 (E-F), 8 (G-H, S), and 10 (I-J) days
post-infection, and from uninfected non-antibiotic (-ABX) treated mice (K-L, O-P), and
uninfected antibiotic (+ABX) treated mice (M-N, Q-R). Tissue was paraffin embedded and
sectioned onto slides. To detect C. difficile spores, an immunofluorescence protocol was applied
to slides by either treating with anti-HMW SlpA antibodies (A-N) or pre-immune serum (O-T),
and then treating with a secondary antibody anti-rabbit Alexa 594 (red). Sections were treated
with the Hoechst 33342 DNA stain (blue). Image scale bar is 5 µm. “E” indicates location of the
epithelium. White dashed line separates inner and outer mucus layer. “OML” indicates location
of outer mucus layer. C. difficile spores are indicated by white arrows and the corresponding
spores are magnified in the black panel to the left of each image (A-J). White arrow with a line
point to background (C-D).
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Figure 9. IFM Analysis of Cecum and Colon After Infection. Cecum and colon tissue were
excised from mice after infection at 15 (A-B), 20 (C-D), 25 (E-F), and 40 (G-H) days postinfection. Tissue was paraffin embedded and sectioned onto slides. To detect C. difficile spores,
an immunofluorescence protocol was applied to slides by treating with anti-HMW SlpA
antibodies and then treating with a secondary antibody anti-rabbit Alexa 594 (red). Sections were
treated with the Hoechst 33342 DNA stain (blue). Image scale bar is 5 µm. “E” indicates
location of the epithelium. White dashed line separates inner and outer mucus layer. “OML”
indicates location of outer mucus layer. C. difficile spores are indicated by white arrows and the
corresponding spores are magnified in the black panel to the left of each image (A-H). White
arrow with a line point to background (E-F).
Quantifying C. difficile Spores Within the Mouse Cecum and Colon During and After
Infection
To quantitatively assess the location of C. difficile spores during and after infection, I
quantified spores within the lumen and mucosa of the cecum and colon. I harvested the cecum
and colon from mice during and after infection and cut tissue sections for fluorescence
microscopy. The remaining tissue was used for spore quantification. The luminal fraction
consisted of the intestinal content that was gently squeezed out of the tissue and diluted in PBS.
Tissue was cut open, exposing the lumen, and rinsed 5 times with PBS to remove any residual
intestinal content. The tissue was placed in a tube with PBS and sonicated to dislodge the
mucosa into solution; this was considered the mucosal fraction. Both the mucosal and luminal
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fractions were heat shocked at 65 C for 30 minutes to kill C. difficile vegetative cells. The two
fractions were serially diluted and plated on TCCFA plates (which are selective for C. difficile)
to obtain CFUs of C. difficile spores. As a negative control, I plated the luminal and mucosal
fractions of an uninfected non-antibiotic treated mouse. This resulted in no growth, indicating
absence of C. difficile spores in an uninfected mouse, as expected.
Spores were quantified from cecum and colon of 2 mice at 2, 4, 6, 8, 10, 15, 20, 25 days
PI and from 3 mice at 40 days PI. The total number of spores for each of the time points PI in the
cecum and colon was calculated by adding the number of CFUs in the luminal plus mucosal
fractions. The cecum had a greater total number of spores than compared to the colon at all time
points PI (2-40 days PI). Next, as part of my analysis, I compared the number of spores in the
luminal and mucosal fractions for each tissue, and the number of spores in the cecum and colon
for each of the fractions. I found that the number of spores was higher in the lumen than the
mucosa, in both the cecum and the colon at all time points PI, except for 4 days PI (Figure 10A).
Within the cecum, on average across all time points PI, there were 1.30 log more spores in the
lumen than the mucosa. Within the colon, on average across all time points PI, except for 4 days
PI, there was an average of 1.68 log more spores in the lumen than the mucosa. At 4 days PI
within the colon, there were 0.15 log more spores in the mucosa than the lumen. When
comparing the number of spores between the lumen of the cecum and colon, there were
consistently more spores within the lumen of the cecum than the colon at all time points PI
(Figure 10A); on average, across all time points PI, there were 0.77 log more spores in the lumen
of the cecum than the lumen of the colon. Interestingly, when comparing the number of spores
between the mucosa in the cecum and colon, there were 1.08 log more spores in the mucosa of
the cecum than colon on average across all-time points PI, except for 4 days PI (Figure 10A). At
4 days PI, there were 0.16 log more spores in the mucosa of the colon than cecum. To determine
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if there are statistically significant number of spores within the mucosa of the cecum than the
colon, I used an Unpaired Student’s T-test (alpha P < 0.05). I found that a statistically significant
number of spores were present in the mucosa of the cecum than the colon at 6, 8, 10, 15, 25, 40
days PI (Figure 10B).
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Figure 10. C. difficile Spore Quantification with the Mouse Lumen and Mucosa of the
Cecum and Colon PI. Colon and cecum of 2 mice at 2, 4, 6, 8, 10, 15, 20, 25 days PI and 3
mice at 40 days PI were excised. The lumen fraction was collected from each tissue by gently
squeezing and collecting the intestinal content in PBS. The mucosal fraction was collected by
exposing the lumen of the tissue, rinsing 5 times with PBS, and sonicating the tissue in PBS to
dislodge mucosa into solution. Fractions were serial diluted and plated on TCCFA plates to
obtain CFUs (A). Error bars indicate standard error of the mean (A) and standard deviation (B).
The mucosal fractions from the colon and cecum from (A) are used to perform an unpaired
Student’s T-test (alpha P < 0.05) in (B). “ns” (not-significant, P > 0.05), * (P ≤ 0.05), ** (P
≤0.01), *** (P ≤ 0.001).
Conclusion
By localizing C. difficile spores within the cecum and colon, using IFM and anti-HMW
SlpA antibodies, I observed spores in either the lumen or the outer mucus layer, and rarely found
them associated with the inner mucus layer or the epithelium (Figure 8, 9). There was a greater
relative abundance of spores located within the lumen of both the cecum and colon at all time
points PI. These spores are likely excreted out of the GI tract as part of the feces and, after
exiting the host, would serve to disseminate the infectious particle for transmittance of disease.
Alternatively, a portion of the spore population in the lumen may associate with the outer mucus
layer due to the proximity between the two locations. As the luminal content moves within the
tissue, spores in the lumen can come in close contact with the outer mucus layer and bind.
Even though localizing spores within the outer mucus layer does not demonstrate that
spores are binding mucin, it does suggest a specific and tight interaction between spores and
mucin. Based on our data, it is likely that a specific interaction between spores and mucin in vivo
does occur. I found that spores are associated exclusively to the outer mucus layer and not to the
epithelium (Figure 8, 9). Even though, I rarely observed spores within the inner mucus layer,
spores were located at the outer and inner mucus layer interface (Figure 8, 9). This indicates that
spores bind the surface of the inner mucus layer, but are not able to penetrate, likely due to the
dense configuration of mucins within the inner mucus layer. Other researchers have
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demonstrated that spores bind to mucin in vitro, indicating that a spore-mucin interaction does
exist (52, 53). However, others have also shown that spores bind epithelial cell lines and ECM
proteins in vitro, suggesting a spore-epithelium interaction in vivo (23, 34). Our IFM data argue
against the association of spores and the epithelium, and instead demonstrate a possible sporemucin interaction in vivo. Our data also suggest a tight interaction between spores and mucin in
vivo. Since spores are present in the outer mucus layer during, and importantly after infection,
the interaction between spores and mucin must be tight enough to allow for persistence in the
outer mucus layer after infection.
Since spores were observed within the outer mucus layer both during and after infection,
this supports the hypothesis that by binding to mucin during infection, spores persist within the
outer mucus layer after infection. Without binding to a host surface and remaining in the lumen,
spores would likely get excreted out of the tissue as feces. Therefore, maintaining a spore
reservoir that is bound to the outer mucus layer would allow spores to remain in the host tissue to
cause relapse. Interestingly, in our mouse model of infection, only 1,000 C. difficile spores are
needed to cause symptoms of CDI in 100 % of mice infected after administration of the
antibiotic cocktail (57). According to our spore quantification data, there are more than 1000
spores associated with the mucosa of the cecum and colon up to 25 days PI (Figure 10). If the
mice from our experiment were administered antibiotics at 25 days PI, disease relapse would
likely occur. Therefore, the outer mucus layer can maintain a sufficient number of spores after
infection that can cause relapse of disease.
The mucosa of the cecum is likely a niche that is conducive for spore persistence. Our
spore quantification data revealed that the cecum has a greater total number of spores (lumen
plus mucosa) than the colon. Furthermore, the number of spores associated with the mucosa of
the cecum is significantly higher than the number of spores within the mucosa of the colon,
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except for 2, 4, and 20 days PI (Figure 10B). These data suggest that the mucosa of the cecum is
a niche that is conducive for persistence and likely serves as a spore reservoir that can cause
relapsing disease.
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Localization of C. difficile Vegetative Cells Within the Mouse Large Intestines During and
After Infection
Introduction
Along with the persistence of C. difficile spores within the GI tract, another potential
cause for relapse is the persistence of C. difficile cells after infection. If cells continue to persist
after infection, they have the potential to reinitiate another cycle of disease. Whether C. difficile
cells persist after infection, and the location at where they persist is not known. Since C. difficile
cells are present within the outer mucus layer during infection, they would likely continue to
persist at that location after infection has resolved (6). Therefore, we hypothesize that C. difficile
cells reside with the mucosal-associated C. difficile spore population in the outer mucus layer
during infection and continue to persist at that location after infection.
To test this hypothesis, cecal and colonic tissue was prepared for microscopy from mice
during and after infection. I first performed fluorescence in situ hybridization (FISH), using a C.
difficile specific probe, to determine the location of vegetative cells, and then IFM, using antiHMW SlpA antibodies, to detect C. difficile spores. A fluorescent stain was also applied to slides
to locate the epithelium and outer mucus layer.
Locating C. difficile Vegetative Cells Within the Mouse Cecum and Colon During and After
Infection
To determine whether C. difficile cells continue to persist within the mouse cecal and
colonic tissue after infection, I first performed FISH to detect vegetative cells, using a C. difficile
specific probe. This C. difficile probe was a fluorescently tagged nucleotide sequence which was
complimentary to the C. difficile 16S rRNA sequence. For the probe to enter C. difficile cells, a
lysis solution containing lysozyme and mutanolysin was first applied to the slides before
application of the probe. The slides were incubated overnight with the probe to allow
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hybridization to occur. To determine if spores reside amongst the mucosal-associated C. difficile
vegetative cell communities both during and after infection, an immunofluorescence protocol
was applied to slides the following day, using anti-HMW SlpA antibodies. The location of the
outer mucus layer was determined by applying a fluorescent DNA stain which would detect the
microbiota located within the outer mucus layer. After performing FISH, immunofluorescence,
and DNA staining, I used fluorescence microscopy to examine the slides. I expected that
vegetative cells will be detected by both the C. difficile probe, which hybridizes the rRNA within
the cell, and anti-HMW SlpA antibodies, which bind SlpA on the surface of the cell. Spores were
expected to be detected by only the anti-HMW SlpA antibodies and not the C. difficile probe. I
also expected that C. difficile vegetative cells will persist after infection and will be present
amongst the C. difficile spore population within the outer mucus layer both during and after
infection. As a negative control for the presence of C. difficile cells, I performed FISH on cecum
and colon sections from mice that were uninfected antibiotic treated and from uninfected nonantibiotic treated mice. There was no fluorescence signal from the cecum or colon of either
uninfected antibiotic or uninfected non-antibiotic treated mice sections, as expected (Figure 7
K-N).
At all time points during infection, C. difficile vegetative cells were found amongst the C.
difficile spore communities within the outer mucus layer (Figure 11A-J). There was a greater
relative abundance of C. difficile vegetative cells within the lumen than the outer mucus layer.
There was also greater relative abundance of cells within the outer mucus layer at early time
points (2, 4, 6 days PI) than late time points (8, 10 days PI) during infection. There were minimal
to no cells associated with the epithelium and the inner mucus layer (Figure 11A-J). The cecum
and colon of an average of three mice per time point were examined during infection. On
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average, for each of the time points, four tissue sections, each containing two pieces of tissue
were examined for the cecum and colon.
At time points after infection, C. difficile vegetative cells were observed within the lumen
or the outer mucus layer of the cecum and colon, and rarely observed associated with the inner
mucus layer or the epithelium at all time points after infection (Figure 12A-J). Also, C. difficile
vegetative cells and spores were present in the same mucosal-associated communities within the
outer mucus layer at all time points after infection (Figure 12A-J). There was a greater relative
abundance of C. difficile cells located within the lumen than the outer mucus layer, and a greater
abundance of cells were present within the outer mucus layer at early time points (15, 20, 25
days PI) than at a late time point (40 days PI) after infection. The cecum and colon of an average
of two mice per time point were examined after infection. On average, for each of the time
points, two tissue sections, each containing two pieces of tissue were examined for the cecum
and colon. At time points both during and after infection, cells were not in close association or in
clumps with one another or with spores, suggesting that cells do not reside in a biofilm-like
structure.
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Figure 11. FISH and IFM Analysis of the Cecum and Colon During Infection. Cecum and
colon tissue were excised from mice during infection at 2 (A-B), 4 (C-D), 6 (E-F), 8 (G-H), and
10 (I-J) days post-infection and from mice that were uninfected antibiotic treated (+ABX) (M-N)
and uninfected non-antibiotic treated (-ABX) (K-L). Tissue was paraffine embedded and
sectioned onto slides. FISH was performed on all sections (A-N) using a C. difficile 16S rRNA
specific probe, conjugated to Alexa 499 (yellow) to detect C. difficile cells. Immunofluorescence
protocol was performed on infected sections only (A-J), using anti-HMW SlpA antibodies and a
secondary antibody anti-rabbit Alexa 594 (red). to detect C. difficile spores. All sections were
treated with the Hoechst 33342 DNA stain (blue). Image scale bar is 5 µm. “E” indicates
location of the epithelium. White dashed line separates inner and outer mucus layer. “OML”
indicates location of outer mucus layer. C. difficile cell and spore are indicated with a white
arrow and magnified in the corresponding panel to the left of each image (A-J).
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Figure 12. FISH and IFM Analysis of the Cecum and Colon After Infection. Cecum and
colon tissue were excised from mice after infection at 15 (A-B), 20 (C-D), 25 (E-F), and 40 (GH) days post-infection. Tissue was paraffine embedded and sectioned onto slides. FISH was
performed using a C. difficile 16S rRNA specific probe, conjugated to Alexa 499 (yellow) to
detect C. difficile cells. Immunofluorescence protocol was performed, using anti-HMW SlpA
antibodies and a secondary antibody anti-rabbit Alexa 594 (red), to detect C. difficile spores.
Sections were treated with the Hoechst 33342 DNA stain (blue). Image scale bar is 5 µm. “E”
indicates location of the epithelium. White dashed line separates inner and outer mucus layer.
“OML” indicates location of outer mucus layer. C. difficile cell and spore are indicated with a
white arrow and magnified in the corresponding panel to the left of each image (A-H).
Conclusion
By performing FISH, I observed that C. difficile cells are present within the cecum and
colon during and after infection. They are either located in the lumen or the outer mucus layer
and are rarely found within the inner mucus layer or associated with the epithelium (Figure 11,
12). Cells that are in the lumen are likely either excreted out of the GI tract as part of the feces or
sporulate before exiting the host to ensure viability in an aerobic environment. None the less,
cells that are within the lumen are not likely retained within the GI tract. However, due to the
proximity of the lumen and the outer mucus layer, cells that are within the lumen can come into
close contact to the outer mucus layer and bind. Whether cells bind mucin at that location or are
present without an interaction is not known. However, our data suggest that like spores, cells
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have a tight and specific interaction with mucin in vivo. Like spores, cells are located exclusively
in the outer mucus layer and not associated with the epithelium (Figure 11, 12). Also, cells are
present within the outer mucus layer after infection, indicating that the cell-mucin interaction
must be tight to allow for persistence after infection at that location. These data suggest that both
cells and spores likely have a similar mechanism of adhesion to mucin. We suggest that both
cells and spores have a protein (SlpA) on the surface which is mediating adhesion to mucin.
Since a bacterial biofilm can allow for persistence, we wanted to know whether C.
difficile biofilm-like structure was present in the outer mucus layer after infection. I expected
cells and spores to reside in clumps or in aggregates in the outer mucus layer, if they are in a
biofilm-like structure. Our data demonstrate that both during and after infection, cells and spores
were located within the outer mucus layer, but do not appear to be in close association with one
another (Figure 11, 12). Even though cells and spores do not appear to be in a biofilm-like
structure, they persist in the outer mucus layer after infection (Figure 12). This indicates that
cells and spores persist through other mechanisms and not by residing in biofilms bound to
mucus. These data again suggest that the surface of cells and spores is conducive in binding
mucus to allow for persistence.
If cells that persist in the outer mucus layer secrete toxins, then they can cause relapse of
disease. Even though we do not know whether cells within the outer mucus layer after infection
produce toxin, it is likely that they do not. Since one environmental factor that effects toxin
production is quorum sensing, the abundance of cells at a location can determine whether toxin is
secreted (65). According to our data, there are more cells located within the outer mucus layer
during infection than after infection and the secretion of toxin during infection is well
documented (10). Because of the fewer number of cells after infection in the outer mucus layer,
as we observed, cells are likely not secreting toxin (Figure 12). It can also be the case that cells
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within the outer mucus layer after infection are secreting toxin, but at levels that are not causing
visible symptoms of disease or inflammation. None the less, if there is a disruption in the GI tract
microbiota of the recovering host, then the vegetative cells that persist after infection can begin
to replicate. This increase in C. difficile cell density can signal toxin production and cause
relapse of disease.
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Determining Whether SlpA Mediates Adhesion of C. difficile Spores to Mucin
Introduction
The persistence of C. difficile spores after infection within the GI tract can cause
relapsing disease. If spores that persist within the GI tract after infection germinate to form
vegetative cells that secrete toxins, then relapse can occur. Our data show that spores are located
within the outer mucus layer both during and after infection (Figure 4, 5, 7, 8). By binding to
mucus during infection, spores can persist within the GI tract after infection. The binding of
spores to mucin in vitro is demonstrated, but the mechanism by which this binding occurs is not
known (52, 53). Interestingly, our laboratory found that a cell surface layer protein, SlpA is
located on the surface of spores. SlpA mediates adhesion of vegetative cells to intestinal
epithelial cells (7). However, whether SlpA mediates adhesion to mucin is not known. We
hypothesize that SlpA on the surface of C. difficile spores is mediating adhesion to mucin.
To test this hypothesis, I optimized in vitro mucin adhesion assays that use commercially
available porcine gastric mucin (PGM) (23, 60). To test whether SlpA on the surface of C.
difficile spores mediates adhesion to mucin, I used our optimized mucin adhesion assay to
measure adhesion of spores that either have SlpA blocked (using anti-HMW SlpA antibodies), or
removed, as compared to adhesion of untreated spores. I expected that if SlpA mediates adhesion
to mucin, then spores that have SlpA blocked or removed would bind less to mucin than
untreated spores.
The use of a slpA genetic mutant is preferred to test the role of SlpA in mediating spore
adhesion to mucin. However, since we do not have access to the only slpA mutant strain that has
been generated, we attempted to remove or block the SlpA protein on the spore surface (1). We
attempted to remove SlpA from the surface of spores by either mechanical agitation or
biochemical treatments. These treatments were expected to remove SlpA, but also other spore
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surface proteins as well. Therefore, we expected that using these treated spores in our mucin
adhesion assay would limit the conclusions that we could make. If there was less adhesion of
spores that have SlpA removed compared to untreated, then we would consider the possibility of
other spore surface proteins, which may have been removed along with SlpA, in mediating
adhesion to mucin. To mitigate this possibility, we applied less harsh treatments first to remove
SlpA. We also blocked SlpA on the surface of spores using anti-HMW SlpA antibodies.
However, we expected that using antibody blocked spores in our mucin adhesion would also
limit the conclusions that we can make. We expected that the complete encirclement of the spore
with the anti-HMW SlpA antibodies can cause steric hinderance that can prevent binding of
other spore surface proteins that might bind to mucin, other than SlpA. Therefore, it is possible
that the anti-HMW SlpA antibodies may indirectly block other proteins, besides SlpA, that
mediate adhesion to mucin. Therefore, we kept these caveats in mind when interpreting the
results.
Removal of SlpA From C. difficile Spore Surface
To determine the role of SlpA in mediating C. difficile spore adhesion to mucin, I
measured adhesion of spores that have SlpA removed and compare that to adhesion of untreated
spores. Even though SlpA is associated to the spore surface, we do not know how SlpA is bound
to the spore. Therefore, I used an assortment of treatments to remove SlpA. We should note that
the removal treatments will not selectively remove SlpA but can remove other spore surface
proteins as well. To limit this possibility, I attempted less harsh treatments first. After growing
14 day in vitro biofilms containing spores, I transferred the biofilms into microcentrifuge tubes
and subjected them to SlpA removal treatments. To determine whether SlpA was removed, I
performed IFM, using anti-HMW SlpA antibodies. If a fluorescence signal that surrounded the
spore was not present, then I concluded that SlpA was removed. As a positive control for the
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removal of SlpA, I performed a protocol that is known to remove coat proteins. I expected that
by removing the coat, SlpA, which is expected to be located on the coat surface, will also be
removed. This protocol entailed incubating spores at 100oC for 5 minutes in a buffered solution
containing sodium dodecyl sulfate (SDS) and dithiothreitol (DTT), followed by vortex for 1
minute and re-incubation at 100ºC for 5 minutes. After performing this protocol and performing
IFM, using anti-HMW SlpA antibodies, there was no fluorescence signal surrounding spores,
indicating absence of SlpA, as expected (Figure 13I).
To remove SlpA, I attempted mechanical agitation protocols that can disrupt an
assortment of loose and strong binding interactions. A less harsh removal using mechanical
agitation entailed 10 washes with PBS, where one PBS wash included suspending the spore
pellet in PBS, vortex for 1 minute, centrifuging to re-pellet, and removing the supernatant.
Performing IFM on this spore suspension revealed a fluorescent ring surrounding the spores,
indicating the presence of SlpA on the spore surface, similar to spores that were not treated
(Figure 13A-B). A more aggressive removal using mechanical agitation included sonication of
the spore suspension, which alters the ultrastructure of the outermost layer of C. difficile spores
(34). This treatment entailed suspending spores in a 50 mM Tris/HCl and 0.5 mM EDTA buffer
(pH 7.5) and sonicating for 10, 1 minute bursts, while cooling on ice for 2 minutes between
bursts. After performing IFM on this suspension, a fluorescent signal around spores was
observed, indicating presence of SlpA (Figure 13C).
The removal of SlpA was also attempted using biochemical extraction protocols. To the
C. difficile 14 day biofilm suspension, I applied the same protocol that our laboratory has used
previously to remove a vegetative cell surface layer protein (EA1) from the surface of B.
anthracis spores. This protocol entailed sequential washes with the following salt and detergent
solutions: 0.5M KCl and 1% glycerol solution, 1M NaCl solution, 0.05% SDS, 0.05M Tris and

71
0.01M EDTA solution, and lastly 0.05% Tween 20 solution. I expected that the salts (KCl and
NaCl) and SDS would disrupt ionic interactions and Tween 20 would disrupt hydrophobic
interactions. The wash steps included suspending the spore pellet in one of the solutions, vortex
for 1 minute, centrifuging to re-pellet, removing the supernatant, and adding the next solution in
sequence. Performing IFM on this spore suspension again revealed a fluorescence signal
surrounding spores, indicating the presence of SlpA on the spore surface (Figure 13D). I repeated
the same protocol but increased the salt concentrations to 3.5M KCl and 4M NaCl. Presence of
SlpA surrounding the spores was still detectable after performing IFM (Figure 13E). I repeated
the same protocol again but increased both the salt (3.5M KCl and 4M NaCl) and detergent
concentrations (5% SDS and 5% Tween 20). After performing IFM, SlpA was still detectable on
the surface of spores (Figure 13F).
To remove SlpA using another biochemical approach, I used a C. difficile spore
purification protocol that has been used to remove vegetative cell debris from the spore
preparation (58, 59). This protocol entailed incubating spores with 0.3mg/mL Proteinase K and
1% Sarcosyl at 37oC for 2 hours followed by 10 washes with PBS. I expected that Proteinase K
would cleave peptide bonds and Sarcosyl would disrupt ionic interactions. After performing this
protocol and IFM, a fluorescence signal was present surrounding spores, indicating presence of
SlpA (Figure 13G). Increasing the Proteinase K and Sarcosyl concentration by approximately
ten-fold (1 mg/mL Proteinase K and 10% Sarcosyl) also resulted in a fluorescence signal
surrounding spores, indicating presence of SlpA (Figure 13H). Since the association of SlpA and
the spore surface could not be disrupted using harsh mechanical or biochemical treatments, I did
not attempt to measure adhesion to mucin of these treated spores.
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Figure 13. IFM Analysis of 14 Day C. difficile Biofilm Spores After SlpA Removal
Treatment. 14 day C. difficile biofilms were either not treated (A) or treated with SlpA removal
treatments including 10 PBS washes (B), sonication (C), salt (0.5M KCl, 1M NaCl) and
detergent (0.05% SDS, 0.05% Tween 20) (D), high salt (3.5M KCl, 4M NaCl) and detergent
(0.05% SDS, 0.05% Tween 20) (E), high salt (3.5M KCl, 4M NaCl) and high detergent (5%
SDS, 5% Tween 20) (F), proteinase K (0.3mg/ml) and sarcosyl (1%) (G), and high proteinase K
(1mg/m) and high sarcosyl (10%) (H). As a control, coat protein extraction was performed (I).
After the SlpA removal treatment, spores were fixed onto slides and IFM, using anti-HMW SlpA
antibodies was performed to determine if SlpA was removed. Phase-contrast microscopy was
used to locate spores. Images were taken at 1000X magnification.
Optimization of an In Vitro C. difficile Spore and Mucin Adhesion Assay
To determine whether SlpA mediates C. difficile spore adhesion to mucin, I attempted to
optimize established mucin adhesion assays (23, 60). Two mucin preparations were purchased as
commercially available lyophilized porcine gastric mucus powder, which included a crude and
partially purified preparation. The partially purified preparation was prepared by the
manufacturer by applying a series of ethanol and sodium chloride precipitation steps to the crude
preparation (66). Both mucin preparations were used separately to optimize two adhesion assays
that differed in mucin immobilization. In one of the adhesion assays, mucin was combined with
agar to form a gel, and in the other, mucin was attached to microtiter wells (23, 60). The general
set-up of both adhesion assays was the following: (step 1) addition of 14 day in vitro biofilms to
either the mucin-agar gels or mucin containing microtiter wells and incubation at 37ºC for 90
minutes to allow for adhesion, (step 2) 3 washes with PBS to remove unbound spores, (step 3)

75
addition of 0.1% Triton-X 100 and incubation at 37ºC for 30 minutes to disrupt binding of spores
to mucin, (step 4) serial dilution and plating to obtain CFUs of spores that were bound to mucin.
By incubating biofilms in aerobic conditions overnight before performing the adhesion assay, I
expected to kill vegetative cells and, therefore, only biofilm spores were expected to be
quantified at the end of the assay. As a control to determine the total number of spores added to
the assay, I performed a separate experiment in which I followed all steps, except for step 2,
which was removal of unbound spores. This control accounted for spores that bind to plastic and
cannot be detached using Triton-X 100, and any effect that Triton-X 100 might have on spore
viability. The percent adhesion was calculated by dividing the number of bound spores by the
total number of spores added to the assay (control), multiplied by 100.
Optimization of a mucin adhesion assay utilizing a mucin-agar gel was done first. This
mucin adhesion assay was previously used to measure adhesion of Lactobacillus rhamnosus,
Bacillus cereus, and Escherichia coli to a mucin-agar gel (60). However, adhesion of C. difficile
was not previously measured using this assay. To form the mucin-agar gels, a ratio of 1:5 agar to
mucin mixture was prepared in sterile distilled water, autoclaved, and 150uL of this mixture was
added to 2mL microcentrifuge tubes. The gels solidified overnight and were used in the adhesion
assay the following day. As a control, I measured adhesion of spores to gels containing only
agar. I expected that if spores bind to mucin, then spore adhesion to the mucin-agar gel should be
greater than the agar gel. The same concentration of agar was used to make the mucin-agar gel
and agar gel. When comparing adhesion of biofilm spores to the mucin-agar gel and the agar gel,
more spores were bound to the agar gel than to the mucin-agar gel (Figure 14A). The same
results were observed when using either the crude or partially purified mucin to form the mucinagar gel.
Since greater adhesion of spores to the agar gel than the mucin-agar gel was an
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unexpected result, I attempted to further optimize the protocol. First, I attempted to decrease
spore binding to agar by blocking gels with bovine serum albumin (BSA). I pre-incubated the
mucin-agar gel and agar gel with various concentrations of BSA suspended in PBS (2%, 10%
BSA) at various temperatures (room temperature, 37ºC) for 120 minutes before performing the
adhesion assay. Blocking gels either resulted in more adhesion to the agar gel compared to the
mucin-agar gel or resulted in similar levels of adhesion to both the agar and mucin-agar gels, as
observed when blocking with 2% BSA at room temperature (Figure 14B). Blocking agar did not
result in a decrease of spore adhesion to agar gel compared to mucin-agar gel. Therefore, I
attempted to replace agar in the mucin-agar gels with another substrate that can potentially bind
less to spores than agar. Since agar was used to immobilize mucin in the mucin-agar gel, other
substrates that could replace agar and immobilize mucin included, agarose and gelatin. I
expected that if spores bind less to agarose or gelatin than agar, then I can replace agar in the
mucin-agar gel. I performed the adhesion assay using gels made of agarose and gelatin and
compared adhesion to the agar gel. Adherence of spores was either the same or more to the
agarose and gelatin gels respectively, than the agar gel (Figure 14C-D). Therefore, replacing agar
with another substrate, such as agarose or gelatin, to form a gel with mucin was not pursued. I
expected that if spores bind to agar and not to mucin, then spore adhesion would be equal
between the agar gel and mucin-agar gel. However, the presence of mucin resulted in less
adhesion to the mucin-agar gel than the agar gel. Therefore, this protocol was not further
optimized and not used to measure C. difficile spore adhesion to mucin.
I optimized another mucin adhesion assay, which utilized mucin coated microtiter wells.
To coat the wells with mucin, crude and partially purified mucin preparations were suspended
separately in PBS (40mg/mL), added to microtiter wells, and incubated at 4oC overnight. Before
performing the adhesion assay, the mucin solution was removed, and wells were washed 3 times
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with PBS to remove any unbound mucin. Adhesion of C. difficile spores to mucin, using PGM
coated microtiter wells, is established in the literature (23). Even though our general set-up of the
mucin adhesion assay followed this protocol, I optimized certain aspects of the assay. In this
mucin adhesion assay, the researchers coated the wells with various concentrations of mucin
(0.04, 0.2, 0.5, and 1mg/mL) (23). Approximately, 10-15% of spores added to the assay adhered
to each of these mucin concentrations (23). Surprisingly, adhesion was highest to wells coated
with 0.04mg/mL mucin and lowest to wells coated with 1mg/mL (23). It is possible that since the
concentration of mucin used to coat the wells was low, spores might be binding to plastic and not
mucin. To limit this possibility, I coated wells with a high concentration of mucin (40mg/mL).
Also, in the established assay, the researchers removed the unbound spores by removing all
liquid from the wells (23). By removing all liquid from the wells, the spore-mucin interaction at
the bottom of the well can be disrupted resulting in removal of spores that were bound. To limit
mechanical disruption of the spore-mucin interaction at the bottom of the well, I left 150uL of
liquid in the wells between wash steps when removing unbound spores, creating a liquid buffer.
After performing the optimized mucin adhesion protocol, 22% and 26 % of spores adhered to
either the crude or partially purified mucin, respectively (Figure 15A). I used this mucin
adhesion protocol to determine the role of SlpA in spore adherence to mucin.
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Figure 14. Adhesion Assay of C. difficile Biofilm Spores to Mucin-Agar Gel. 14 day biofilms
were added to gels made of PGM and agar (5:1 ratio) (A-B), agar only (A-D), agarose only (C),
or gelatin only (D). Spores were incubated with gels at 37oC for 90 minutes, followed by 3
washes with PBS, addition of Triton-X 100, incubation at 37oC for 30 minutes, and plating to
obtain CFUs of bound spores. As a control to determine total number of spores added to the
assay, spores were added to either mucin-agar gel (A-B) or agar only gel (C-D). Percent
adhesion was calculated by dividing CFUs of bound spores with the control, multiplied by 100.
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In panel B, gels were blocked with either 2% or 10% BSA at either room temperature (RT) or
37oC before performing the assay. In panel A, error bars represent the standard deviation of two
experimental repeats.
C. difficile Spore and Mucin Adhesion Assay
To determine if SlpA is mediating C. difficile spore adhesion to mucin, I measured
adhesion to mucin using spores that had SlpA blocked with anti-HMW SlpA antibodies and
spores that were untreated. I expected that if SlpA is mediating spore adhesion to mucin, then
spores with blocked SlpA would adhere less to mucin than untreated spores. To prepare mucin
coated wells, I suspended 40mg/ml of either crude or partially purified mucin in PBS, placed
150uL of the mucin solution in microtiter wells, and incubated at 4oC overnight on slow shaking.
Before the addition of spores, I removed any unbound mucin by washing wells 3 times with
PBS. To block SlpA on the surface of spores, I incubated 14 day biofilms with various
concentrations of anti-HMW SlpA antibodies (1:10, 1:100, 1:1000) at 37oC for 30 minutes.
Spores that were not treated with antibody were incubated with PBS only. As a negative control,
I incubated spores with serum (1:100) from a naïve rabbit. Spores were washed once to remove
unbound antibodies, and 5x106 spores were added to wells coated with either crude or partially
purified mucin. As a control to determine the total number of spores added to the assay, spores
that were not treated with antibody were added to wells that were incubated with PBS only and
no mucin. The mucin adhesion assay was performed according to the optimized parameters. The
adherence of spores that were not incubated with any antibodies was 33% and 18% for wells
incubated with crude and partially purified mucin, respectively, and incubating spores with the
naïve serum had similar results (Figure 15B). However, incubating spores with 1:10 and 1:100
anti-HMW SlpA antibody concentrations resulted in more adhesion than the no antibody control
(Figure 15B). Incubating spores with 1:1000 anti-HMW SlpA antibody concentration resulted in
similar levels of adhesion as the no antibody control (Figure 15B).
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Figure 15. Adhesion Assay of SlpA Blocked C. difficile Biofilm Spores to Mucin Coated
Microtiter Wells. 14 day biofilms were added to mucin coated microtiter wells and incubated at
37oC for 90 minutes, followed by 3 washes with PBS, addition of Triton-X 100, incubation at
37oC for 30 minutes, and plating to obtain CFUs of bound spores (A-B). In panel B, before
performing the assay, spores were incubated with anti-HMW SlpA antibodies (1:10, 1:100,
1:1000) or naïve rabbit serum (1:100) (control), or with no antibodies (control). As a control to
determine total number of spores added to the assay, spores were added to wells incubated with
PBS only and no mucin (A-B). Percent adhesion was calculated by dividing CFUs of bound
spores by the total number of spores added to the assay, multiplied by 100. “C” indicates wells
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coated with crude mucin. “PP” indicates wells with partially purified mucin. “AB” indicates
antibodies.
Conclusion
To test whether SlpA mediates adhesion of C. difficile spores to mucin, I performed a
mucin adhesion assay using spores that have SlpA blocked with anti-HMW SlpA antibodies.
Spores from a slpA genetic mutant would be ideal. However, we did not have access to the single
slpA mutant isolated to date (1). Therefore, I used anti-HMW SlpA antibodies to selectively
block SlpA on the surface of spores. By performing a mucin adhesion assay with spores that
were either treated with anti-HMW SlpA antibodies or untreated, I tested whether SlpA mediates
adhesion to mucin. I expected that if SlpA mediates adhesion of spores to mucin, then spores
with blocked SlpA would bind less to mucin than untreated spores. However, the percent
adhesion of spores that were treated with anti-HMW SlpA antibodies was either approximately
the same, or more than, spores that were untreated (Figure 15B). Based on the results, we cannot
conclude that SlpA does not mediate adhesion of spores to mucin, due to the set-up of our mucin
adhesion assay.
One explanation of the result is that the surface of spores treated with anti-HMW SlpA
antibodies has greater or similar adhesion to mucin than the surface of untreated spores. After
incubating spores with anti-HMW SlpA antibodies, the antibodies coat the surface of spores.
While the Fab (fragment antigen-binding) region of the antibodies is bound to the SlpA antigen,
the Fc (fragment crystallizable) region of the antibodies can bind mucin through non-specific
interactions, resulting in adhesion to mucin. To limit the non-specific interaction between the Fc
region of the anti-HMW SlpA antibodies and mucin, a blocking agent can be added to the
solution used to incubate spores with the anti-HMW SlpA antibodies.
Another explanation of the results is that the anti-HMW SlpA antibody treated spores are
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binding the microtiter well plastic more than untreated spores. To bind mucin to wells, I used
microtiter plates with a coating which has high affinity to molecules with mixed hydrophilic and
hydrophobic domains. Even though mucin is expected to coat the entirety of the well, there could
be regions with exposed plastic that can bind the Fc region of the anti-HMW SlpA antibodies. To
limit the binding of the antibodies to the exposed plastic, a blocking agent can be incubated in
the wells prior to performing the assay. Even though it is possible that untreated spores are
binding plastic, I expected that the adhesion to plastic would be the same across each well. Since
all wells were incubated with the same concentration of mucin, the region of exposed plastic
should be the same across all wells. However, if the binding affinity of antibody treated spores is
greater to plastic than untreated spores, then percent adhesion of antibody treated spores can be
similar or more than untreated spores. In this case, it would be necessary to block the microtiter
plates with a blocking agent to limit binding to plastic. Interestingly, in vitro mucin adhesion
assays that demonstrate C. difficile spore adhesion to PGM or to mucin producing cells lines do
not block the plates prior to performing the assay (23, 52, 53). The reason for not blocking plates
prior to performing the assay is not clear. However, in measuring adhesion to a specific
substrate, such as mucin, it would be necessary to limit any non-specific binding. Therefore, due
to the set-up of our assay, whether SlpA mediates spore adhesion to mucin remains an open
question.

CHAPTER FOUR
DISCUSSION
In this work, I localized C. difficile cells and spores by employing a mouse model of CDI
and performing FISH and IFM on mouse cecal and colonic tissue sections. I also quantified the
number of spores within the lumen and mucosa of the mouse large intestine. The following are
conclusions that are made as a result of this work: (i) C. difficile spores are present in the outer
mucus layer amongst C. difficile vegetative cells during infection, (ii) C. difficile cells and spores
are present in the outer mucus layer after infection has resolved. Lastly, I attempted to determine
if SlpA on the surface of C. difficile spores mediates spore adhesion to mucin in vitro. Even
though our mucin adhesion assay did not detect SlpA and mucin binding, utilizing other
approaches to measure this interaction might successfully address this open question.
C. difficile During Infection
A major conclusion of this work is that during infection (2-10 days PI), spores are present
in the outer mucus layer in the mouse cecum and colon, amongst the mucosal-associated C.
difficile vegetative cells. Some studies using mouse and hamster models of CDI agree with our
finding that cells associate with the mucus layer overlaying the epithelium during infection (6,
26, 27). In contrast to our findings, other studies have demonstrated that C. difficile cells are
located within crypt crevasses and tissue surfaces (67, 68). However, in these studies, the mucus
layer was not fixed in the tissue sections, which were observed using scanning electron
microscopy. Without mucus fixation, only the surface of C. difficile cells and intestinal epithelial
cells was visible and not the location of the mucus layer. Therefore, these studies do not account
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for C. difficile cell association with the mucus layer. Importantly, none of these studies or others
have examined the location of C. difficile spores during infection. Even though C. difficile spores
do not directly cause disease, they can germinate to form vegetative cells that produce toxins,
which cause disease. Our finding that spores associate with the outer mucus layer during
infection can have important implications for relapsing disease. If spores that are located within
the outer mucus layer bind mucus during disease, then they can persist after infection has
resolved. Spores that have persisted in the outer mucus layer can then germinate to form
vegetative cells, initiating another cycle of infection.
The presence of C. difficile cells and spores in the outer mucus layer during infection
supports the hypothesis that cells and spores bind the outer mucus layer to initiate colonization in
the large intestines. One of the key open questions in understanding CDI pathogenesis is to
determine how C. difficile initiates colonization. Our finding that C. difficile cells and spores are
located within the outer mucus layer as early as 2 days PI, indicates that association with mucus
is one of the key early steps in colonization. Since I found that cells and spores continue to
persist in the outer mucus layer throughout infection (2-10 days PI), it is likely that by binding to
the mucus layer, they remain colonized. If C. difficile cells and spores are only located in the
lumen and do not associate and bind to a host surface, then they would get excreted out of the
host. Even though I observed most of the C. difficile cells and spores located within the lumen, a
portion of cells and spores was also present within the outer mucus layer throughout infection.
This suggests that by binding to the outer mucus layer, a portion of the C. difficile cell and spore
population continues to remain colonized throughout infection and is not excreted out of the
tissue.
Our data also supports the hypothesis that C. difficile cells and spores bind the outer
mucus layer and not the epithelial layer in vivo. However, there are multiple in vitro studies that
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demonstrate adhesion between C. difficile (cells and spores) and intestinal epithelial cells where
the authors hypothesize that C. difficile likely binds the epithelium in vivo (7, 16, 23, 24, 34). In
contrast, our in vivo data demonstrate that C. difficile cells and spores are located within the outer
mucus layer and not close to the epithelium at any time point during infection, indicating that
cells and spores bind the outer mucus layer in the large intestines exclusively. Collectively, our
data argue that C. difficile cells and spores bind the outer mucus layer to colonize the large
intestines during infection.
C. difficile After Infection
Another major conclusion of this work is that after infection (15-40 days PI), C. difficile
cells and spores are present within the outer mucus layer in the mouse cecum and colon. Our
finding that C. difficile cells and spores persist within the outer mucus layer after infection can
have important implications for understanding recurrent disease. How recurrent CDI occurs is an
important question that needs to be addressed, considering approximately one-fifth of individuals
who have had CDI experience recurrence (4). If C. difficile cells and spores bind to a host
surface and persist after infection, then spores have the potential to germinate to form vegetative
cells that secrete toxins and cause relapsing disease. In the literature, it is established that spores
are present within the host GI tract after infection by quantifying the number of C. difficile
spores within the feces of both CDI patients and mice that are infected (29, 30, 35). However, the
location of C. difficile cells and spores is not documented but can help to determine the GI tract
surface cells and spores likely bind to persist. By localizing C. difficile cells and spores in the
mouse cecum and colon after infection, using FISH and IFM, I found that C. difficile cells and
spores are present within the outer mucus layer at time points after infection (15-40 days PI).
Quantification of spores in the mouse cecum and colon revealed that spores are present within
the mucosa even up to 40 days PI. Our data support the hypothesis that by binding to the outer

86
mucus layer, C. difficile cells and spores persist after infection, creating a reservoir of C. difficile
within the outer mucus layer that can potentially cause relapsing disease.
Even though our data support that C. difficile cells and spores bind mucus to persist
within the GI tract after infection, we do not know if association with the mucus layer is
necessary for persistence. If C. difficile cells and spores associate and bind to the mucus layer to
persist, then a disrupted mucus layer should result in reduced persistence. To test if association to
the mucus layer is necessary for persistence, we can localize C. difficile cells and spores within
the large intestines of a Muc2 knockout mouse after infection. Muc2 is the major glycoprotein
secreted by goblet cells that forms the inner and outer mucus layers. In a Muc2 knockout mouse,
the mucus layers are absent (69). I would expect minimal if any C. difficile cells and spores to
localize within the large intestines of a Muc2 knockout mouse after infection if cells and spores
bind only the mucus layer to persist.
However, we need to note that there are morphological differences between the mucosa
of a Muc2 knockout and a WT mouse that can affect persistence. Histological changes in the
colon of a Muc2 knockout mouse include, thickening of the mucosa, flattening of epithelial cells,
and infiltration of inflammatory cells (69). Without the mucus layer and a luminally exposed
epithelium, C. difficile cells and spores can bind to other parts of the mucosa, such as the
intestinal epithelial cells. However, if C. difficile cells and spores associate with the outer mucus
layer and not to other parts of the mucosa after infection in WT mice, as our data demonstrate,
then changes to the other parts of the mucosa are not expected to affect persistence in a Muc2
knockout mouse.
Also, we need to note that a Muc2 knockout mouse likely possess a different microbiota
than a WT mouse. Since a Muc2 knockout lacks an outer mucus layer where the microbiota
resides, an absence of this niece likely changes the diversity and composition of the microbiota.
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It is possible that the Muc2 knockout mouse possesses a GI tract microbiota that can either
promote or inhibit persistence of C. difficile relative to WT. Therefore, the use of germ-free WT
and germ-free Muc2 mice will account for the difference in the microbiota. Keeping the
differences in the microbiota and mucosal morphology between the Muc2 knockout mouse and
WT in mind, the use of the stated experimental set-up should help us test if association with the
outer mucus layer is necessary for persistence. If it is the case that the mucus layer is necessary
for persistence, then therapeutics can be designed to target the mucus layer during infection to
prevent persistence of C. difficile cells and spores that can cause relapse.
Another open question regarding persistence of C. difficile cells and spores after infection
is how cells and spores remain colonized within the unstable outer mucus layer. The inner and
outer mucus layers are composed of a polymeric mucin net-like structure. However, the structure
of the outer mucus layer is inherently weak due to cleavage events caused by the host and
resident microbiota, which ultimately leads to a loose and expanded layer (71). The outer mucus
layer is readily consumed by the resident microbiota, and continuously shed into the lumen, due
to the peristaltic movements of the intestines and movement of the intestinal content within the
tissue (14). How enteric bacteria, whether commensals or pathogens like C. difficile, persist in
the continuously shed outer mucus layer is unknown. It is likely that C. difficile remains within
the outer mucus layer by proliferating within the layer and concomitantly associating with the
outer mucus layer from the lumen. C. difficile cells associated with the outer mucus layer can
replicate and spores can germinate, ultimately populating the layer. As a part of the outer mucus
layer is shed into the lumen, the C. difficile cells and spores that are associated with mucus are
also released into the lumen. Once the cells and spores in the lumen encounter the mucus layer
again, before getting excreted out of the GI tract, they re-associate with the layer.
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Optimization of In vitro Mucin Adhesion Assays
When utilizing a mucin adhesion assay to measure SlpA mediated adhesion of C. difficile
spores to mucin, I found two main caveats that must be considered when designing and
optimizing the assay. One major caveat to consider is that C. difficile spores can readily bind
abiotic (stainless steel) and biotic surfaces (human-derived cell lines) (70). Therefore, when
utilizing a mucin adhesion assay, adhesion of C. difficile spores to surfaces besides mucin must
be accounted for in the design of the assay before measuring the role of SlpA. In the literature, a
mucin adhesion assay that measures adhesion of intestinal bacteria, not including C. difficile, to
mucin using a mucin-agar gel is established (60). I used this in vitro assay to measure adhesion
of C. difficile spores to the mucin-agar gel. To determine if spores are binding specifically to
mucin and not agar, I measured spore adhesion to a gel containing only agar. I found that spores
bound more to the agar gel than the mucin-agar gel. Using a blocking agent (BSA) to block agar
did not decrease spore binding to the agar gel as compared to the mucin-agar gel. I also measured
spore binding to a gelatin gel and agarose gel and found that spores bound more or the same to
these substrates, respectively, than to an agar gel. These data indicated that C. difficile spores
have a propensity to bind substrates, including but not limited to agar, agarose, and gelatin,
which must be considered when designing the mucin adhesion assay.
C. difficile spore binding to plastic must also be considered when optimizing the mucin
adhesion assay. In the literature, a mucin adhesion assay that measures C. difficile spore binding
to mucin coated microtiter wells is also established (23). In this assay, microtiter wells were
coated with low (0.04 mg/mL) and high (1 mg/mL) concentrations of mucin (23). Unexpectedly,
more spores bound to wells that were coated with a lower concentration of mucin (23). It is
likely that wells with a lower concentration of mucin had regions of exposed plastic that spores
bound to more readily. Therefore, to limit the possibility of spore binding to plastic, I incubated
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wells with a high concentration of mucin (40mg/mL). I expected that coating wells with a higher
concentration of mucin will limit regions of exposed plastic. For future directions, to further
prevent C. difficile spore binding to plastic, the mucin coated microtiter wells can be incubated
with a blocking agent to limit spore binding to plastic. Even though C. difficile spore binding to
plastic is not documented, it should be considered when optimizing the mucin adhesion assay.
The second major caveat to consider is that the mucin adhesion assay must accurately
detect SlpA-mucin interaction. If SlpA and mucin binding is weak, and the mucin adhesion assay
can only detect strong binding, then a false negative result is expected. In the in vitro assay
which uses mucin coated microtiter wells, spores that were not bound to mucin were separated
from spores bound to mucin by adding PBS and subsequently removing all liquid from the well
(23). By removing all liquid from the wells, spore-mucin binding which occurs at the bottom of
the well is likely disrupted due to mechanical agitation. If SlpA mediated spore-mucin binding is
weak, then it is likely that removal of all liquid from the wells results in disruption of binding
and a false negative result. Therefore, to prevent disruption of spore-mucin binding, I optimized
the assay by retaining a liquid at the bottom of the well. I added PBS to the well, gently pipetted
in and out three times, and removed a portion of the liquid, leaving a portion at the bottom of the
well where I expected the spore-mucin binding to occur. I expected that retaining liquid at the
bottom of the well will decrease the mechanical agitation which can disrupt spore-mucin
binding. Since we do not know whether SlpA and mucin interaction occurs or if it is strong or
weak, the threshold for detection of the mucin adhesion assay should be low to be able to
decipher a weak interaction from no interaction.
In vitro Assay to Test SlpA-Mucin Binding
Even though we expected to use our in vitro mucin adhesion assay to address whether
SlpA mediates C. difficile spore adhesion to mucin, the role of SlpA in mucin adhesion remains
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undetermined. In our assay, we determined the role of SlpA in mucin adhesion by measuring
adhesion of spores that have SlpA blocked, using anti-HMW SlpA antibodies, and untreated
spores to mucin coated microtiter wells. The results showed that the percent adhesion of
antibody treated spores was more than or equal to spores that were untreated. Since we used
spores that are coated with antibodies, there is a possibility that the antibodies are causing a nonspecific interaction with mucin. Even though this result does not support a SlpA-mucin
interaction, it does not argue against this interaction either. Therefore, the role of SlpA in mucin
adhesion remains undetermined. If it was the case that anti-HMW SlpA antibody treated spores
bind less to mucin than untreated spores, then we could assert a role of SlpA in mucin adhesion.
However, due to our negative result, it is likely that if SlpA binds mucin, then the interaction
affinity is likely modest.
As a future direction, another in vitro assay can be designed to determine if there is SlpAmucin interaction. In this purposed assay, we can apply recombinant SlpA protein to microtiter
wells coated with mucin and determine whether recombinant SlpA protein binds mucin coated
wells. The set-up of this experiment will be similar to an established protocol (53). Briefly, in
our experiment, we will coat wells with commercially available porcine gastric mucin, block
wells with a blocking agent (BSA), and add recombinant SlpA protein to wells. Recombinant
SlpA and recombinant LMW and HMW subunits have been purified previously in the literature
(40). After removal of unbound SlpA, we will measure the amount of bound SlpA by adding
primary rabbit anti-HMW SlpA antibodies and secondary anti-rabbit horse radish peroxidase
conjugated antibodies. Then, we will measure the optical density using a spectrophotometer. I
expect that if SlpA-mucin interaction occurs in vivo, then recombinant SlpA protein will bind to
mucin coated wells in vitro.
There are specific advantages to using this purposed experimental set-up, as compared to
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the set-up followed in our study. A major advantage of the purposed experimental set-up is that a
positive or negative result will either support or negate a SlpA-mucin interaction. This was not
the case in the experimental set-up followed in our study. Even though a positive result in our
study would have been strong evidence that SlpA-mucin interaction occurs, a negative result
does not support that a SlpA-mucin interaction does not occur. Another advantage of this
approach is that we will not need to consider spore binding to non-mucin substrates, such as
plastic or agar. Since we observed spores binding to agar, even after using a blocking agent, the
use of recombinant SlpA and no spores in this assay will circumvent the possibility of spores
binding to non-mucin substrates. Lastly, another advantage of this approach is that we will not
use spores that are coated with anti-HMW SlpA antibodies. To block SlpA on the surface of
spores, we incubated spores with anti-HMW SlpA antibodies. We expected to measure adhesion
between antibody treated and untreated spores to determine whether SlpA mediates spore
adhesion to mucin. Since the antibodies coat the surface of spores, we needed to consider
antibody interaction with mucin in this set-up when interpreting the results. Therefore, in this
purposed experimental set-up, we will not need to use spores incubated with anti-HMW SlpA
antibodies to demonstrate the role of SlpA. Rather, in this assay we will measure SlpA and
mucin binding directly. We will measure binding of the recombinant SlpA to wells that are either
coated or not coated with mucin. The wells that are not coated with mucin will account for nonspecific binding. By subtracting binding of recombinant SlpA to wells coated with mucin, with
wells that are not coated with mucin, we should be able to measure SlpA-mucin binding.
Using the purposed experimental set-up, we can determine if SlpA-mucin interaction
occurs. If it is the case that SlpA binds to mucin in vitro, then the conclusion that SlpA on the
surface of C. difficile spores contributes to mucin binding in vivo is supported. Even though we
would determine SlpA and mucin interaction in vitro, using the purposed assay, the extent to
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which SlpA contributes to spore adhesion to mucin in vivo will remain an open question.
Whether the presence of SlpA on the surface of spores is necessary or sufficient for spore
binding to mucin in vivo will not be addressed using the purposed assay. None-the-less, our data
demonstrate that spores that are located within the outer mucus layer have SlpA present on the
surface and that these SlpA encased spores persist in the outer mucus layer even after infection.
Therefore, these data suggest that SlpA on the surface of spores can cause persistence through an
interaction with mucin, and this specific SlpA-mucin interaction can be determined using the
purposed in vitro assay.
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